Maternal and Child Health, Nutrition, and Hiv by Smith, Emily Rose
Maternal and Child
Health, Nutrition, and Hiv
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Smith, Emily Rose. 2016. Maternal and Child Health, Nutrition,
and Hiv. Doctoral dissertation, Harvard T.H. Chan School of Public
Health.
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32644541
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
 
 
MATERNAL AND CHILD HEALTH, NUTRITION, AND HIV 
EMILY ROSE SMITH 
A Dissertation Submitted to the Faculty of 
The Harvard T.H. Chan School of Public Health 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Science 
in the Department of Global Health and Population 
Harvard University 
Boston, Massachusetts. 
November 2016 
 
 
 
 ii 
 
Dissertation Advisor: Dr. Wafaie Fawzi          Emily Rose Smith 
Maternal and Child Health, HIV, and Nutrition 
Abstract 
Reducing maternal and child mortality was established as a global priority with the 
signing of the Millennium Declaration in September 2000.  Neonatal vitamin A supplementation 
and very early breastfeeding initiation are scalable interventions which may improve infant 
survival.  Although breastfeeding has proven benefits for infant health, the potential health 
consequences of breastfeeding for HIV-infected women are not well studied. 
In paper one, “The effect of neonatal vitamin A supplementation on morbidity and 
mortality at 12 months: A randomized trial”, we assessed the efficacy of neonatal vitamin A 
supplementation (NVAS) in reducing infant morbidity and mortality. Using data from an 
individually randomized clinical trial of 31,999 infants in Tanzania, we found that NVAS did not 
affect the risk of death or the incidence of morbidities.  However, we noted that postpartum 
maternal vitamin A supplementation modified the effect of neonatal vitamin A supplementation 
on infant mortality. 
In paper two, “Effect of delayed breastfeeding initiation on infant survival: a 
systematic review and meta-analysis”, our objective was to synthesize the evidence regarding 
the association between breastfeeding initiation time and infant morbidity and mortality. We 
pooled five studies, including 136,047 infants. We found a clear dose-response relationship; the 
risk of neonatal mortality increased with increased delay in breastfeeding initiation. We found a 
similar pattern when the analysis was restricted to exclusively breastfed infants or low 
birthweight infants.  There was limited evidence regarding the association between breastfeeding 
initiation time and infant morbidity and growth.  We concluded that health policy frameworks 
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and models to estimate newborn and infant survival should consider the independent survival 
benefit associated with early initiation of breastfeeding. 
In paper three, “Breastfeeding and Maternal Health among HIV-infected Women in 
Tanzania”, our objective was to assess the relationship between infant feeding practices and the 
incidence of maternal mortality, morbidity, and indicators of poor nutritional status from six 
weeks to two years postpartum in a prospective cohort of Tanzanian women living with HIV.  
We concluded that breastfeeding may be associated with mixed health outcomes. Additional 
research should investigate whether HIV-infected women require nutritional support, in addition 
to antiretroviral therapy, during and after lactation. 
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Abstract 
 
Background: Neonatal vitamin A supplementation (NVAS) is an intervention hypothesized to 
reduce infant morbidity and mortality. The objective of this study was to assess the efficacy of 
neonatal vitamin A supplementation in reducing infant morbidity and mortality and assess 
potential sources of heterogeneity of the effect of NVAS. 
 
Methods: We completed an individually randomized, double-blind, placebo-controlled trial in 
Tanzania. Infants were randomized within three days of birth to a single dose of vitamin A 
(50,000 IU) or placebo. We assessed infants at one and three days after supplementation, as well 
as one, three, six, and 12 months after supplementation. We included all live births in the 
analysis and used relative risks and 95% confidence intervals to assess the risk of mortality and 
hospitalization by 12 months. We used general estimating equations to assess the incidence of 
morbidities during infancy.  
 
Results: A total of 31,999 infants were enrolled in the study between August 2010 and March 
2013. At 12 months, vitamin A did not reduce all-cause infant mortality (RR 1.04; 95% CI 0.92-
1.16), nor affect hospitalization (RR 1.09; 95% CI 0.97-1.22) or all-cause morbidity (RR 1.00; 
95% CI 0.96-1.05). Postpartum maternal vitamin A supplementation modified the effect of 
neonatal vitamin A supplementation on mortality at 12 months (p-value, test for interaction = 
0.04). Among infants born to women who received a mega-dose of vitamin A after delivery, 
NVAS appeared to increase the risk of death (RR 1.12; 95% CI 0.98-1.29), while the risk of 
death among infants born to women who did not receive a mega-dose was reduced (RR 0.86; 
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95% CI 0.70-1.06). We noted no effect modification of the effect of NVAS by infant gender, 
birthweight, or maternal HIV status.  
 
Conclusion: NVAS did not affect the risk of death or incidence of common childhood 
morbidities.  However, this study sheds light on potential sources of heterogeneity of the effect 
of neonatal vitamin A supplementation which should be further examined in a pooled analysis of 
all NVAS trials.   
 
Keywords: Neonatal Vitamin A Supplementation, Infant Mortality, Hospitalization, Morbidity, 
Tanzania  
 
Key Messages 
 The recent completion and analysis of the three largest neonatal vitamin A 
supplementation trials (NEOVITA) found conflicting results regarding the efficacy of 
this intervention in reducing infant morbidity and mortality. A meta-analysis combining 
this data with that of seven previous trials found important heterogeneity in mortality 
effects. 
 Overall, we found no evidence that neonatal vitamin A supplementation in Tanzania 
reduces the risk of mortality, hospitalization, or morbidity during infancy. 
 Data from this trial suggests that maternal vitamin A status may modify the effect of 
neonatal vitamin A supplementation. 
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Introduction 
Despite improvements in child survival in the past four decades, an estimated 6.3 million children 
under the age of five died in 2013 (1). Although child mortality continues to decline, there has 
been slower progress in reducing infant mortality. Interventions to reduce neonatal and infant 
mortality are needed, and there is evidence that vitamin A supplementation can reduce morbidity 
and mortality among children aged 6 to 59 months (2). A number of trials to assess the efficacy of 
neonatal vitamin A supplementation have had conflicting findings. While some trials have shown 
clear benefit associated with supplementation (3, 4), others suggest a null or possibly harmful 
effect (5, 6). The reason for qualitative differences in the effect of neonatal vitamin A 
supplementation between these trials is not well understood. 
 
The efficacy of neonatal vitamin A supplementation may be modified by baseline maternal or 
infant characteristics. A meta-analysis including all published trials to date (7), suggested that 
geographic region, which is highly correlated with the population prevalence of vitamin A 
deficiency, may explain the heterogeneity of trial results. Specifically, trials performed in Asia 
(also classified as having moderate or severe maternal vitamin A deficiency) (3, 4, 8-10) had a 
13% reduced risk of mortality from supplementation to six months (RR: 0.87, 95% CI: 0.78, 0.96), 
whereas  African trials (countries also classified as having mild or no maternal deficiency)   (5, 6, 
11-13) showed a 10%  increased risk of mortality associated with neonatal vitamin A 
supplementation (RR: 1.10, 95% CI: 1.00,1.21).  A trial in Guinea Bissau among normal 
birthweight infants (given 50,000 IU or 25,000 IU vitamin A) and a trial in Zimbabwe among 
HIV-infected women also found no effect of neonatal vitamin A supplementation on mortality (14, 
15).  The differences in findings between trials conducted in Asia and Africa may also be 
5 
 
attributable to variability in the prevalence of HIV, given that vitamin A supplementation has been 
associated with higher risk of mother-to-child transmission of HIV (16). Low birthweight or 
prematurity are also potential effect modifiers, as vitamin A deficiency is more prevalent among 
these infants, and these infants may benefit from supplementation (17). Child sex and timing of 
vaccination have also been hypothesized to modify the effect of vitamin A supplementation on 
mortality (18). 
 
We examined the effects of neonatal vitamin A supplementation on the incidence of all-cause and 
cause-specific infant morbidity as measured by hospitalization and caregiver report of illness in 
the NEOVITA Tanzania trial (5).  Additionally, we assessed whether the efficacy of neonatal 
vitamin A supplementation in reducing infant morbidity and mortality was modified by baseline 
maternal and infant characteristics. 
 
Methods 
Study Design and Population 
The data was collected as part of an individually randomized, placebo controlled trial conducted 
in Tanzania from August 2010 through March 2014. Infants were randomized at home or health 
facility to receive a mega-dose of vitamin A (50,000 IU)  or placebo on the day of birth or within 
three days (n=31,999).  Details regarding the randomization, blinding, intervention, and follow up 
are described elsewhere (5, 19). Infants were eligible for randomization if they were able to feed 
orally, the family intended to stay in the study area for at least 6 months, and parents provided 
informed consent. Follow up data were collected during home visits one and three days after 
supplementation, as well as one, three, six, and 12 months after supplementation.  The study 
6 
 
protocol was approved by the Institutional Review Boards of the Harvard School of Public Health, 
Ifakara Health Institute, Medical Research Coordinating Council of Tanzania, and by the WHO 
Ethical Review Committee. The trial is registered at Australian New Zealand Clinical Trials 
Registry (ANZCTR) -ACTRN12610000636055. 
 
Outcome Definitions 
The primary outcomes of interest included mortality, hospitalization, and morbidity between 
supplementation and one year (360 days).  We assessed cause-specific hospitalization and 
symptom-specific morbidity occurring between supplementation and one year (360 days). We also 
present morbidity and mortality outcomes assessed six months (180 days) as secondary endpoints. 
 
Potential Effect Modifiers 
Potential effect modifiers of the effect of vitamin A on mortality specified a priori in the trial 
protocol include infant sex (male or female), birthweight (<2500 g and >2500 g), received maternal 
large-dose vitamin A supplementation (yes or no), and socioeconomic status. Two additional 
maternal characteristics were considered post-hoc as potential effect modifiers including: maternal 
vitamin A intake classified by the Institute of Medicine (IOM) recommended daily allowance 
(RDA) [below RDA (<700 µg/day), within RDA (700 to <3,000 µg/day), above RDA (>3,000 
µg/day)]  (20) and maternal HIV status at delivery (positive or negative).  Additionally, we 
combined information from the maternal large-dose vitamin A supplementation data (yes or no) 
and the maternal vitamin A intake data (below RDA or within RDA) to create “maternal vitamin 
A status” categories: 1) High (maternal supplementation + within RDA), 2) Medium-High 
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(maternal supplementation + below RDA), 3) Medium-Low (no maternal supplementation + 
within RDA), 4) Low (no maternal supplementation + below RDA).  
 
Data Collection and Categorization  
Infant death and date of death were ascertained by research staff at home visits. Hospitalization 
was defined as an inpatient admission to the hospital since the last home visit, which was 
transcribed from the child health card or as reported by the mother in the case of missing child 
health card. Research staff recorded the admission date and reason for hospitalization as either a) 
acute lower respiratory infection or pneumonia, b) diarrhea, c) fever or malaria, or d) other reason. 
Data from the first case of hospitalization was used in the analysis. Caregiver report of morbidity 
was assessed by one month caregiver recall at one, three, six, and 12 month home visits. During 
home visits, research staff asked caregivers if the child had any of the following symptoms in the 
past month: cough; refusal to eat, drink, or breastfeed; fever; difficulty in breathing; chest 
retraction; convulsions; vomiting; diarrhea. 
 
Child sex and birthweight were assessed by a study nurse or dosing supervisor at randomization. 
Postpartum maternal vitamin A supplementation (yes or no) was assessed by research staff at 
randomization and again at 1 month postpartum. Maternal education and pregnancy history were 
assessed by field interviewers during a baseline interview. A wealth index was generated based 
on household ownership of assets, and households were categorized into wealth quintiles based 
on this index. For all women enrolled in the trial during the first year of recruitment, maternal 
dietary intake was assessed around the time of birth by trained field interviewing using a semi-
quantitative food frequency questionnaire (FFQ) (21-25). Based on monthly recall of 108 
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commonly consumed foods, we calculated average daily servings and translated this data into 
nutrient intake based on the Tanzania Food Composition Tables (26). Maternal HIV status 
(positive, negative, unknown) was abstracted from the delivery ward record books for the subset 
of women who delivered at health facilities which maintained registry books where HIV status at 
delivery was recorded.  The time of breastfeeding initiation and whether colostrum was given to 
the infant was assessed by a study nurse or dosing supervisor at the time of dosing and again at 
one and three days after dosing if the infant had not initiated breastfeeding at the time of dosing.  
The age of the child at dosing was calculated as the number of hours between the time of birth 
and time of dosing. Gestational age at birth was calculated based on maternal report of last 
menstrual period. Size for gestational age at birth was calculated based on INTERGROWTH 
standard (27). Gestational age and size for gestational age was categorized in the following four 
groups: preterm (<37 weeks gestation) small for gestations age (<10th percentile in weight for 
gestational age), preterm appropriate for gestational age (>10th percentile in weight for 
gestational age), term (>37 weeks) small for gestational age, or term appropriate for gestational 
age. 
 
Statistical Analysis 
The cohort was characterized using baseline data regarding household, maternal, and infant 
characteristics using means or proportions for continuous and categorical data respectively.  
Including all live-births, we estimated risk ratios and their corresponding 95% confidence intervals 
to assess the relationship between vitamin A supplementation and the risk of mortality and 
hospitalization within 12 months. We used log binomial general estimating equations (GEEs) with 
an exchangeable working covariance matrix to assess the relationship between vitamin A 
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supplementation and morbidity within 12 months, allowing for repeated episodes of morbidity for 
each child. For the subgroup analyses, potential effect modification by maternal and infant 
characteristics (including infant sex, birthweight, maternal vitamin A supplementation, maternal 
HIV status, and maternal vitamin A intake) was assessed using the likelihood ratio test comparing 
the full and reduced log binomial regression models. We also present mortality, hospitalization, 
and morbidity analyses within the first 6 months (180 days) as secondary analyses. P-values less 
than 0.05, in conjunction with 95% confidence intervals and the magnitude of effect estimates, 
were used to identify results of importance. Analysis was completed using SAS version 9.2 (Cary, 
NC). 
 
Results 
Among 32,843 infants assessed for eligibility, a total of 31,999 infants were enrolled in the study 
between August 2010 and March 2013. Among those enrolled, 15,995 were randomized to the 
vitamin A group and 16,004 were randomized to the placebo group (Figure 1.1).  Between 
supplementation and one year (360 days), 779 (4.9%) infants were lost to follow up in the 
vitamin A group and 762 (4.8%) infants were lost to follow up in the placebo group. 
 
The mean age at supplementation was 15.5 (SD 12) hours in the vitamin A group and 15.4 (SD 
12) in the placebo group; about 80% of infants were supplemented within 24 hours after birth. 
Mean birthweight was 3.02 (SD 1) kilograms in both groups.  More than 75% of all women 
received a mega-dose of vitamin A after delivery (as part of standard of care in Tanzania), and 
the median value of dietary intake of vitamin A for mothers was 940 µg/day (IQR 574-1389).  
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Figure 1.1 Trial Profile 
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Vitamin A Group
(n=15995)
Placebo Group
(n=16004)
n (%) n (%)
Male sex 8443 (52.8) 8340 (52.1)
Birthweight <2500 grams 1908 (11.9) 1974 (12.3)
Maternal education
1
None 1335 (9.0) 1310 (8.8)
Primary 11988 (80.9) 12066 (81.3)
Secondary 1491 (10.1) 1472 (9.9)
Received maternal vitamin A supplementation 12122 (76.8) 12091 (76.6)
Colostrum given to infant 15390 (97.4) 15416 (97.6)
Parity
1
1 3872 (29.5) 3843 (29.2)
2-3 5785 (44.1) 5745 (43.7)
>4 3455 (26.3) 3551 (27.0)
Time of dosing
1 
<24 hours 12774 (79.9) 12824 (80.1)
24-47 hours 2939 (18.4) 2881 (18.0)
> 48 hours 282 (1.8) 299 (1.9)
Gestational age & size for gestational age
1 
Term AGA 6768 (66.4) 6738 (65.8)
Term SGA 1705 (16.7) 1688 (16.5)
Preterm AGA 1670 (16.4) 1771 (17.3)
Preterm SGA 46 (0.5) 46 (0.4)
Initiation of breastfeeding
1 
<1 hour 14083 (88.3) 14169 (88.9)
2-23 hours 1726 (10.8) 1670 (10.5)
>24 hours 138 (0.9) 105 (0.7)
Maternal HIV status
HIV infected 139 (0.9) 155 (1.0)
HIV uninfected 2747 (17.2) 2708 (16.9)
Not assessed 13109 (82.0) 13141 (82.1)
Maternal vitamin A dietary intake
<700 µg/day 1018 (6.4) 1007 (6.3)
700 to <3000 µg/day 1950 (12.2) 1969 (12.3)
>3000 µg/day 28 (0.2) 32 (0.2)
Not assessed 12999 (81.3) 12996 (81.2)
Table 1.1 Baseline demographic and health characteristics of mothers and infants (n=31999)
1
These numbers do not add to 100% due to missing data
12 
 
Treatment groups were well balanced in regards to demographic, maternal, and infant 
characteristics (Table 1.1).  
 
At 12 months, vitamin A did not reduce all-cause infant mortality. There were 566 (3.5%) deaths 
in the vitamin A group and 546 (3.4%) deaths in the placebo group (RR 1.04; 95% CI 0.92-1.16). 
NVAS did not reduce all-cause hospitalizations or morbidity. There were 596 (3.7%) 
hospitalizations in the vitamin A group and 547 (3.4%) hospitalizations in the placebo group (RR 
1.09; 95% CI 0.97-1.22). NVAS did not affect the incidence of common childhood illnesses 
through 12 months, with a similar number of caregiver reported morbidity events in both groups 
(RR 1.00; 95% CI 0.96-1.05) (Table 1.2).  Similar results were observed in secondary analyses 
of mortality, hospitalization, and morbidity within six months of age (Supplementary Table 1A). 
 
All potential effect modifiers were assessed, and mortality at 12 months did not differ by any 
characteristic (including sex, birthweight, maternal HIV status, maternal vitamin A dietary 
intake, and socioeconomic status (data not shown)), except by postpartum maternal vitamin A 
supplementation (Table 1.3).  The relative risk of mortality from supplementation to 12 months 
comparing NVAS to placebo for those whose mothers received a large dose of vitamin A was 
1.12 (95% CI 0.98-1.29), while the relative risk for those infants whose mother did not receive 
postpartum vitamin A supplementation was 0.86 (95% CI 0.70-1.06) (p-value, test for interaction 
= 0.04).  A similar trend was observed by overall maternal vitamin A intake (post-partum 
vitamin A supplementation and dietary intake). Among children born to mothers with high 
overall vitamin A dietary intake (who received a post-partum vitamin A supplement and had 
vitamin A dietary intake within the recommended daily allowance (RDA) according to their food 
13 
 
n
2
N
2
n
2
N
2
Mortality  (All-Cause) 566 15995 546 16004 1.04 (0.92,1.16) 0.54
Hospitalization  (All-Cause) 596 15995 547 16004 1.09 (0.97,1.22) 0.14
ALRI 215 15995 197 16004 1.09 (0.90,1.32) 0.37
Diarrhea 142 15995 127 16004 1.12 (0.88,1.42) 0.36
Fever 360 15995 325 16004 1.11 (0.96,1.29) 0.17
Other 136 15995 122 16004 1.12 (0.87,1.42) 0.38
Morbidity  (All-Cause) 4129 38880 4125 38962 1.00 (0.96,1.05) 0.88
Diarrhea 1006 38880 1016 38962 0.99 (0.91,1.09) 0.86
Diarrhea & Vomitting 578 38880 557 38962 1.04 (0.92,1.18) 0.53
Diarrhea & Vomitting & Fever 518 38880 502 38962 1.03 (0.91,1.18) 0.61
Diarrhea & Refused Feeding 449 38880 441 38962 1.02 (0.89,1.18) 0.77
Fever 2543 38880 2521 38962 1.01 (0.96,1.07) 0.69
Fever & Cough 1008 38880 1036 38962 0.98 (0.89,1.07) 0.59
Fever & Difficulty Breathing 583 38880 552 38962 1.06 (0.93,1.20) 0.38
Fever & Cough & Difficulty Breathing 505 38880 469 38962 1.08 (0.94,1.23) 0.28
Cough 2125 38880 2159 38962 0.99 (0.93,1.05) 0.68
Table 1.2. The effect of neonatal vitamin A supplementation on infant mortality, hospitalization, and morbidity at 12 months.
Vitamin A Placebo
2
 n is the number of events (i.e.  deaths, hospitalizations, morbidity cases). N is the number of infants for mortality and hospitalization 
analysis. N is the number of household visits for morbidity analysis.
1
Risk ratio for morbidity outcomes were estimated by GEE log binomial model with an exchangeable working covariance matrix.
Risk Ratio
1     
(95% CI)
p-value
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n
1
N
1
n
1
N
1
Overall [N=31,999] 566 15995 546 16004 1.04 (0.92,1.16) 0.54
Sex  [N=31,994]
Male 312 8443 324 8340 0.95 (0.82,1.11) 0.52
Female 254 7549 222 7662 1.16 (0.97,1.39) 0.10
Birthweight [N=31,983]
<2500 grams 138 1908 120 1974 1.19 (0.94,1.51) 0.15
>2500 grams 428 14077 426 14024 1.00 (0.88,1.14) 0.99
Maternal Vitamin A Supplementation [N=31,559]
Yes 408 12122 362 12091 1.12 (0.98,1.29) 0.10
No 152 3662 178 3684 0.86 (0.70,1.06) 0.16
Maternal HIV Status  [N=5,749]
HIV infected 15 139 10 155 1.67 (0.78,3.60) 0.18
HIV uninfected 65 2747 59 2708 1.09 (0.77,1.54) 0.64
Maternal Vitamin A Dietary Intake  [N=6,004] 1
<700 µg/day 36 1018 41 1007 0.87 (0.56,1.35) 0.53
700 to <3000 µg/day 75 1950 65 1969 1.17 (0.84,1.61) 0.36
>3000 µg/day 0 28 2 32 -
1
 n is the number of deaths. N is the number of infants
Table 1.3. The effect of neonatal vitamin A supplementation on infant mortality (0-12 months), stratified by subgroup. (n=31999)
Number of newborns supplemented
Risk Ratio 
(95% CI)
p-value
p-value
test for 
interaction
Vitamin A Placebo
0.15
0.09
0.21
0.04
0.31
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n
1
N
1
n
1
N
1
Overall 109 2911 106 2909 1.02 (0.79,1.34) 0.84
Maternal vitamin A supplementation & dietary intake 
2
High Maternal supplementation + adequate VA dietary intake 52 1418 39 1415 1.33 (0.88-2.00)
Maternal supplementation + inadequate VA dietary intake 27 750 27 720 0.96 (0.57-1.62)
No maternal supplementation + adequate VA dietary intake 22 487 26 506 0.88 (0.51-1.53)
Low No maternal supplementation + inadequate VA dietary intake 8 256 14 268 0.60 (0.26-1.40)
2
 Vitamin A (VA). Adequate VA dietary intake is defined as <700 µg/day. Inadequate VA dietary intake is defined as 700 to <3000 µg/day.
1
 n is the number of deaths. N is the number of infants
0.070.04
Table 1.4. The effect of neonatal vitamin A supplementation on infant mortality (0 to 12 months), stratified by maternal vitamin A 
supplementation and maternal vitamin A dietary intake. (n=5820)
Number of newborns 
Risk Ratio 
(95% CI)
p-value
test for 
trend
p-value
test for 
interaction
Vitamin A Placebo
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frequency questionnaire), NVAS was associated with an increased risk of infant mortality (RR 
1.33; 95% CI 0.88-2.00). Children born to women with the lowest maternal vitamin A status (no 
maternal supplementation and vitamin A intake below the RDA according to their food 
frequency questionnaire) had a 40% reduced risk of death associated with NVAS (RR 0.60; 95% 
CI: 0.26-1.40) (Table 1.4). Including maternal vitamin A status as an ordinal covariate in the 
model resulted in a p-value for the test for trend of 0.04 and a p-value for the test of interaction 
of 0.07.  Qualitatively similar results were observed for effect modification by maternal 
supplementation and overall vitamin A dietary intake in secondary analyses restricted to events 
in the first six months of life (Supplementary Table 1B, Supplementary Table 1C). 
 
Discussion 
We found that neonatal vitamin A supplementation did not reduce infant mortality or the 
incidence of hospitalization. Our findings are in accord with those from a systematic review 
(conducted prior to the conclusion of the three recent NVAS trials) that found no evidence of an 
effect of  NVAS on hospitalization (RR: 0.75; 95% CI 0.26 to 2.16), although the authors noted 
that the quality of available evidence was low (28). However, NVAS was associated with an 
increased risk of hospitalization at six months in the companion NEOVITA trial in Ghana (RR 
1.11; 95% CI 1.00 to 1.22) (6).  Similarly, a neonatal vitamin A supplementation trial in south 
India, as well as a trial among older children in Indonesia, found an increased incidence of acute 
respiratory infection among children supplemented with vitamin A (VA) (29, 30).  Additionally, 
research among children hospitalized for ARI found that vitamin A supplementation increased 
the severity of symptoms (31-33).  Increased severity of illness is hypothesized to be the result of 
the proinflammatory immune responses associated with VA (34).  We did not find any evidence 
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of effect modification of the effect of neonatal vitamin A supplementation on mortality at six and 
12 months by child sex.  This is consistent with a meta-analysis completed prior to completion of 
the three recent NEOVITA trials (35). 
 
We found there was no difference in the incidence of common childhood morbidities at six or 12 
months when comparing infants randomized to receive vitamin A at birth and those who were 
not.  Our results regarding hospitalization and morbidity are contrary to the hypothesis that 
vitamin A supplementation affects mortality by reducing the incidence or severity of infant 
morbidity (30, 36, 37). This hypothesis was biologically plausible, as vitamin A is known to play 
an important role in immune function (34).   Human and animal models illustrate that vitamin A 
helps maintain and improve epitheilia integrity (including those in the respiratory and 
gastrointestinal tract) and may down-regulate production of proinflammatory cytokines in 
response to specific pathogens. Furthermore, observational data has shown maternal vitamin A 
deficiency (VAD) is associated with increased morbidity in children.  For example, maternal 
night blindness during pregnancy was associated with an increased risk of diarrhea, dysentery, 
and acute respiratory infections (ARI) between birth and six months of age among a cohort of 
infants in South India (38). Other observational research confirms that VAD children are more 
likely to be carriers of Streptococcus pneumoniae (Spn) (39-41) (an important cause of ARI) and 
have increased rates of ARI morbidity and mortality (42, 43). However, randomized trials in 
Bangladesh and south India found no difference between the vitamin A and placebo groups in 
the proportion of infants carrying Spn at three and four months respectively (44, 45).  Our results 
are consistent with a meta-analysis including neonatal vitamin A supplementation and maternal 
vitamin A supplementation (MVAS) plus NVAS trials, which found no effect on morbidity 
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between supplementation and six months (46). Similar morbidity results have been documented 
among trials assessing the efficacy of vitamin A supplementation among children age six to 56 
months (29, 36, 47, 48).  
 
We found evidence that maternal vitamin A status may modify the effect of neonatal vitamin A 
supplementation.  In this trial NVAS appeared to be beneficial for infants born to mothers who 
were not supplemented with vitamin A, while infants born to women who received postpartum 
vitamin A supplementation demonstrated a higher risk of mortality associated with neonatal 
vitamin A supplementation.  This finding is consistent with the hypothesis that the prevalence of 
vitamin A deficiency is an important source of heterogeneity among the recent NVAS trials (7). 
The NEOVITA trials in Ghana and Tanzania both suggested the possibility of an increased risk 
of mortality associated with NVAS, and the prevalence of vitamin A deficiency (<0.70 µmol/L 
serum retinol A) among a subset of mothers enrolled in the trials was low in both settings 
(Ghana:  < 3% VAD (6) ; Tanzania: 8% VAD (5)). Additionally, the prevalence of postpartum 
vitamin A supplementation was high in both settings (Ghana: 50% supplemented; Tanzania: 76% 
supplemented). In contrast, about 12% of women in the companion trial in India trial were 
vitamin A deficient and no mothers received postpartum vitamin A supplementation, and in this 
context NVAS was associated with a reduced risk of mortality from supplementation to six 
months (3).  A factorial designed trial of maternal and neonatal vitamin A supplementation trial 
was conducted in Bangladesh and found no interaction between maternal and neonatal vitamin A 
supplementation, although the statistical power to detect a moderate or small degree of 
interaction was limited (8). Similarly, a factorial designed trial in Zimbabwe found no interaction 
between maternal and neonatal vitamin A supplementation among an analysis of HIV-uninfected 
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mothers (13). Notably, as of 2011 the World Health Organization no longer recommends 
maternal postpartum vitamin A supplementation (49). 
 
We did not find clear evidence that maternal HIV status modified the effect of neonatal vitamin A 
supplementation.  However, there was a trend showing increased risk of mortality associated with 
NVAS among infants born to HIV-infected mothers.  HIV-exposed neonates supplemented with 
vitamin A were two times more likely than those in the placebo group to die before six months, 
and they had a 67% increased risk of death by one year.  Although our cohort for this subgroup 
analysis was small, our trial is one of two NVAS trials in which the HIV status of mothers was 
known.  In a trial conducted in Zimbabwe among HIV-infected women that randomized woman 
and infant pairs to a) postpartum maternal vitamin A supplementation (MVAS) alone, b) NVAS 
alone, c) both MVAS and NVAS, or d) placebo, the unadjusted hazard ratio for child mortality 
from enrollment to 24 months, comparing neonatal vitamin A supplementation (without maternal 
vitamin A supplementation) to placebo was 1.21 (95% CI: 0.99-1.46, p-value = 0.05) (15). Using 
fixed-effects meta-analysis, the pooled effect size comparing NVAS to placebo, among infants 
born to HIV-infected women in the Tanzania and Zimbabwe trials, is 1.23 (95% CI: 1.02-1.49) 
(Supplementary Figure 1A). This suggests that NVAS may be harmful for children born to HIV-
infected mothers.  In the Zimbabwe trial, there was an increased risk of mother to child 
transmission of HIV among the NVAS group, compared to placebo (15). Similarly, a randomized 
trial conducted among HIV-infected mothers in Tanzania found vitamin A was associated with a 
higher risk of mother to child transmission of HIV (16). As a result, increased mother to child 
transmission may partially explain why we found a trend of increased risk of death associated with 
neonatal vitamin A supplementation among infants born to HIV-infected mothers.  
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There are several strengths of this study. First, this is the largest randomized trial of neonatal 
vitamin A supplementation in sub-Saharan Africa.  Detailed baseline data were collected for all 
mothers and infants, comprehensive longitudinal data about infant illness were collected, and loss 
to follow-up was less than 5% at one year. Furthermore, hospitalizations were assessed from the 
child medical card throughout the course of infancy, thus providing a high quality measure of 
severe morbidity. Finally, these data provide perhaps the only opportunity to look at maternal HIV 
status as a modifier of the effect of neonatal vitamin A supplementation, as additional trials of 
NVAS among children born to HIV-infected mothers are unlikely. One limitation of this research 
is that we used caregiver recall to assess morbidity. Further, mothers were asked to report 
morbidity within the last 30 days at one, three, six, and 12 months and as a result, there are no 
caregiver reports of morbidity for more than half of infancy. Thus, the data reported here are likely 
an underestimate of the true incidence of infant morbidities.  Nevertheless, the analytical methods 
we used are well suited for data collected by an unbalanced visit schedule.  Finally, although this 
is a large randomized trial, we may lack statistical power to detect moderate to small degree of 
interaction in all subgroups. Further, maternal vitamin A dietary intake and HIV status data were 
collected in only a subset of women enrolled in the trial. Our finding of effect modification by 
maternal vitamin A status may have occurred by chance, and it is important these results are 
replicated in other trials.  
 
Overall, our findings are consistent with the hypothesis that NVAS does not affect the risk of 
infant mortality or the incidence of common childhood morbidities.  Furthermore, this study 
generates additional hypotheses about the potential sources of heterogeneity of the effect of 
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neonatal vitamin A supplementation on infant health, which should be further examined in a 
pooled analysis of all NVAS trials.   
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n
2
N
2
n
2
N
2
Mortality  (All-Cause) 407 15995 372 16004 1.09 (0.95,1.26) 0.20
Hospitalization  (All-Cause) 332 15995 303 16004 1.10  (0.94,1.28) 0.24
ALRI 129 15995 113 16004 1.14 (0.89,1.47) 0.30
Diarrhea 62 15995 43 16004 1.44 (0.98,2.13) 0.06
Fever 193 15995 170 16004 1.14 (0.93,1.39) 0.22
Other 78 15995 76 16004 1.03 (0.75,1.41) 0.87
Morbidity  (All-Cause) 2070 24947 2097 25014 0.99 (0.93,1.06) 0.81
Diarrhea 388 24947 441 25014 0.88 (0.77,1.02) 0.09
Diarrhea & Vomitting 219 24947 261 25014 0.84 (0.70,1.02) 0.08
Diarrhea & Vomitting & Fever 204 24947 244 25014 0.84 (0.69,1.03) 0.09
Diarrhea & Refused Feeding 196 24947 222 25014 0.89 (0.72,1.09) 0.26
Fever 1143 24947 1169 25014 0.98 (0.91,1.07) 0.71
Fever & Cough 445 24947 466 25014 0.96 (0.84,1.10) 0.59
Fever & Difficulty Breathing 278 24947 292 25014 0.96 (0.80,1.14) 0.61
Fever & Cough & Difficulty Breathing 228 24947 239 25014 0.96 (0.79,1.17) 0.68
Cough 1118 24947 1143 25014 0.98 (0.91,1.07) 0.72
1
Risk ratio for morbidity outcomes were estimated by GEE log binomial model with an exchangeable working covariance matrix.
2
 n is the number of events (i.e.  deaths, hospitalizations, morbidity cases). N is the number of infants for mortality and hospitalization 
analysis. N is the number of household visits for morbidity analysis.
Supplementary Table 1A. The effect of neonatal vitamin A supplementation on six-month mortality, hospitalization, and 
morbidity (0-6 months).
Risk Ratio
1     
(95% CI)
p-value
Vitamin A Placebo
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n
1
N
1
n
1
N
1
Overall [N=31,999] 407 15995 372 16004 1.09  (0.95,1.26) 0.20
Sex  [N=31,994]
Male 233 8443 215 8340 1.07 (0.89,1.29) 0.47
Female 174 7549 157 7662 1.12 (0.91,1.39) 0.28
Birthweight [N=31,983]
<2500 grams 106 1908 87 1974 1.26 (0.96,1.66) 0.10
>2500 grams 301 14077 285 14024 1.05 (0.90,1.24) 0.53
Maternal Vitamin A Supplementation [N=31,559]
Yes 284 12122 249 12091 1.14 (0.96,1.35) 0.13
No 117 3662 119 3684 0.99 (0.77,1.27) 0.93
Maternal HIV Status  [N=5,749]
HIV infected 9 139 5 155 2.01 (0.69,5.85) 0.19
HIV uninfected 45 2747 45 2708 0.99 (0.65,1.49) 0.95
Maternal Vitamin A Dietary Intake  [N=6,004]
<700 µg/day 22 1018 30 1007 0.73 (0.42,1.25) 0.24
700 to <3000 µg/day 57 1950 48 1969 1.20 (0.82,1.75) 0.35
>3000 µg/day 0 28 1 32 -
1
 n is the number of deaths. N is the number of infants
Supplementary Table 1B. The effect of neonatal vitamin A supplementation on six-month mortality (0-6 months), stratified by subgroup. 
(n=31999)
Number of newborns supplemented
Risk Ratio 
(95% CI)
p-value
p-value
test for 
interaction
Vitamin A Placebo
0.73
0.27
0.36
0.21
0.17
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n
1
N
1
n
1
N
1
Overall 77 2911 78 2909 0.99 (0.72-1.35) 0.93
Maternal vitamin A supplementation & dietary intake 
2
High Maternal supplementation + adequate VA dietary intake 37 1418 26 1415 1.42 (0.86-2.33)
Maternal supplementation + inadequate VA dietary intake 15 750 18 720 0.80 (0.41-1.58)
No maternal supplementation + adequate VA dietary intake 19 487 22 506 0.90 (0.49-1.64)
Low No maternal supplementation + inadequate VA dietary intake 6 256 12 268 0.52 (0.20-1.37)
2
 Vitamin A (VA). Adequate VA dietary intake is defined as <700 µg/day. Inadequate VA dietary intake is defined as 700 to <3000 µg/day.
0.004 0.07
1
 n is the number of deaths. N is the number of infants
Supplementary Table 1C. The effect of neonatal vitamin A supplementation on six-month mortality (0 to 6 months), stratified by maternal 
vitamin A supplementation and maternal vitamin A dietary intake. (n=5820)
Number of newborns 
Risk Ratio 
(95% CI)
p-value
test for 
trend
p-value
test for 
interaction
Vitamin A Placebo
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Supplementary Figure 1A. Fixed-effects meta-analysis for the effect of neonatal vitamin A supplementation (NVAS) on infant 
mortality among infants born to HIV-infected women.
Overall  (I-squared = 0.0%, p = 0.423)
Tanzania (Smith 2016)
Zimbabwe (Humphrey 2006)
ID
Study
1.23 (1.02, 1.49)
1.67 (0.78, 3.60)
1.21 (0.99, 1.46)
ES (95% CI)
100.00
6.06
93.94
Weight
%
  
.278 3.6
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ABSTRACT 
Background: Early breastfeeding initiation is recommended, but not always considered an 
independent intervention to improve infant survival.  
Methods: We conducted a systematic review and meta-analysis to assess the relationship 
between very early breastfeeding initiation (<1 hour after birth) compared to delayed initiation 
(2-23 hours and >24 hours after birth) of breastfeeding on infant morbidity and mortality. We 
also assessed the association between early initiation (<24 hours of birth) compared to initiation 
24 hours or more after birth on the same outcomes.  
Results: We identified 4825 records after searching Pubmed, Embase, Web of Science, 
CINAHL, Popline, LILACS, AIM, and Index Medicus. We pooled five ‘moderate quality’ 
studies of 136,047 infants that examined the association between very early breastfeeding 
initiation and neonatal mortality. Compared to infants who initiated breastfeeding <1 hour after 
birth, infants who initiated breastfeeding 2-23 hours after birth had a 33% greater risk of 
neonatal mortality (95% CI: 13-56%, I2=0%), and infants who initiated breastfeeding >24 
hours after birth had a 2.19-fold greater risk of neonatal mortality (95% CI: 1.73-2.77, I2=33%). 
Among the subgroup of infants exclusively breastfed in the neonatal period, those who initiated 
breastfeeding >24 hours after birth had an 85% greater risk of neonatal mortality compared to 
infants who initiated <24 hours after birth (95% CI: 29-167%, I2=33 %).  
Conclusions: Policy frameworks and models to estimate newborn and infant survival, as well 
as health facility policies, should consider the independent effect of early breastfeeding 
initiation.  
Key Words:  breastfeeding initiation, neonatal mortality, infant mortality, infant morbidity, 
infant nutrition
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Key Messages 
 Our review provides new insight on the increased risk of neonatal mortality associated 
with delayed breastfeeding initiation and demonstrated a clear dose-response relationship; 
the risk of neonatal mortality increased with increased delay in breastfeeding initiation. 
 We found that delayed breastfeeding initiation was associated with a similar, increased 
risk of neonatal mortality among low birthweight infants and among those exclusively 
breastfeeding the neonatal period. 
 We found limited evidence that delayed breastfeeding initiation is associated with 
increased risk of morbidity such as diarrhea, hypothermia, and umbilical cord infection. 
However, we could not produce pooled estimates due to differences in exposure and 
outcome definitions. 
 We conclude that there is insufficient evidence regarding delayed breastfeeding initiation 
and nutritional status. Additional analyses utilizing data from high quality, prospective 
cohorts would strengthen the overall quality of the evidence. 
 This review provides evidence that early breastfeeding initiation should be considered 
independently within policy frameworks or when models such as LiST estimate the 
survival benefits of breastfeeding. Breastfeeding promotion programs and health facility 
policies should also emphasize the importance of early initiation of breastfeeding, in 
addition to promoting exclusive breastfeeding. This is particularly relevant for countries, 
where neonatal and infant mortality rates are high, most women already exclusively or 
predominantly breastfeed their infants, and delay of initiation of breastfeeding beyond the 
first hour of life is common.  
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INTRODUCTION  
 
Five million deaths in children younger than five years were reported globally in 2015; almost 
half (46%) of these occurred in the neonatal period [1]. An even a greater number of children are 
affected by prematurity, malnutrition, and septicaemia, which can result in serious physical and 
neurological sequelae [2]. Interventions that can be implemented at scale, starting before birth 
and continuing throughout the postnatal period, are needed to reduce mortality and morbidity in 
children and young infants [2]. Currently, only 50% of infants in the world are breastfed during 
the first hour of life, and 60% are exclusively breastfed [3]. The World Health Organization 
(WHO) recommends that newborns initiate breastfeeding within one hour of birth, but this 
recommendation is not supported by an official WHO guideline.  Additional evidence is needed 
to inform public health investment and to facilitate the implementation of breastfeeding 
promotion programs. 
 
Systematic reviews published in 2013 and 2015 reported that early breastfeeding initiation 
(defined in these reviews as initiation within 24 hours of birth) was associated with reduced 
neonatal mortality [4, 5].  However, no association was found  in a subgroup analysis which 
examined risks among exclusively breastfed infants [4],  and early breastfeeding initiation was 
not included as an independent intervention in the recent Lancet 2013 Nutrition Series [6]. 
Substantial data on the association between early breastfeeding initiation and neonatal mortality 
has recently become available [7-11], including new data from large cohorts of mothers and 
infants who participated in three neonatal vitamin A trials in Ghana, India, and Tanzania [12-14].  
Data from these cohorts was used to examine the association between very early breastfeeding 
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initiation (defined as initiation within one hour of birth) and neonatal and post-neonatal 
mortality. These trials have also provided new data regarding early initiation among exclusively 
breastfed infants [15].   
 
This paper reports the results of a systematic review of all studies published through December 
2015 and updates pooled estimates of associations between delayed breastfeeding initiation and 
neonatal mortality. We assessed the relationship between very early initiation of breastfeeding 
(within one hour of birth) compared to delayed initiation (2-23 hours and 24 hours or more after 
birth) on neonatal mortality (<28 days). We also compared breastfeeding initiation within 24 
hours of birth to initiation 24 hours or more after birth in order to update the results of the 
previous meta-analyses. We further examined the relationship between breastfeeding initiation 
time and infant morbidity and growth.  
 
METHODS 
Protocol and registration  
The protocol for this review was developed by the co-authors after examining existing review 
articles. We registered the protocol with the International Prospective Register of Systematic 
Reviews (PROSPERO) (Registration Number CRD42015032321). We followed MOOSE 
Guidelines for the meta-analysis of observational data while conducting the search, analysis and 
writing the manuscript [16]. 
 
Inclusion and exclusion criteria 
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We included observational studies (e.g. cross-sectional studies, cohort studies, and case-control 
studies) and randomized control trials, if they examined the association between breastfeeding 
initiation time and mortality, morbidity, or nutrition outcomes from birth through 12 months of 
age in a population of infants who all initiated breastfeeding. There were no date restrictions. 
Studies were excluded if they were non-human studies, case reports or case study designs, or if 
the paper was published in abstract form only.  
 
Definitions 
The exposure of interest was breastfeeding initiation time. We assessed the relationship between 
very early initiation (within one hour of birth) compared to delayed initiation (2-23 hours and 24 
hours or more after birth). We also compared breastfeeding initiation less than 24 hours to 24 
hours or more.  
 
Specific mortality outcomes of interest included: neonatal mortality (<28 days), infant mortality 
through six months (<180 days), and infant mortality through 12 months (<360 days). Specific 
morbidity and nutrition outcomes of interest included: diarrhea, respiratory infection, sepsis, 
omphalitis, hypothermia, weight loss, weight for age (WAZ), length-for- age (LAZ), weight-for-
length (WLZ), and hospitalization. 
 
Search  
We conducted electronic searches from December 9-15, 2015. We searched Pubmed, Embase, 
Web of Science, CINAHL, Popline, LILACS, AIM, and Index Medicus for the Eastern 
Mediterranean Region. The search strategy included: (i) terms to identify papers regarding 
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breastfeeding, AND (ii) terms to identify papers regarding timing OR initiation, AND (iii) terms 
for mortality OR morbidity outcomes.  There were no date restrictions. The full search strategy 
used for each database is available in Appendix 1.   
 
Study selection, data collection, and quality assessment  
Two reviewers independently assessed the titles and abstracts of all studies, removed duplicates, 
and categorized each paper as eligible, ineligible, or unclear using the eligibility criteria defined 
above. Disagreements were resolved through consultation with a third reviewer. Two reviewers 
independently extracted data for all studies that met the inclusion criteria including: study 
characteristics, study quality, and the effect estimates showing the relationship between 
breastfeeding initiation time and infant morbidity and mortality. When available, we used 
mortality estimates that excluded deaths in the first two to four days of life in order to rule out 
reverse causality. The quality of included studies was assessed using criteria developed in 
accordance with the World Health Organization (WHO) Child Health Epidemiology Reference 
Group (CHERG) (Table 2.1) and the overall quality of evidence was assessed using GRADE 
guidelines [17, 18].  
 
Analyses 
We pooled relative risks and 95% confidence intervals for all outcomes with two or more 
included studies. Because no heterogeneity was apparent, data synthesis was conducted using 
fixed effects meta-analysis. Heterogeneity of effects were assessed visually using Forest Plots of 
relative risks, quantified by the I2, and tested by the Q statistic tests [19]. Q tests with p values 
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Table 2.1. Criteria used to classify the quality of included studies. 
Study Design Selection Bias Information Bias Attrition bias Confounding Reverse Causality
High RCT
Loss to follow up 
<10%
Moderate -
Loss to follow up 
10-<15%
Low Observational
Loss to follow up 
15-<20%
Very Low -
Loss to follow up 
>20%
Model adjusts for 
gestational age or 
low birthweight. 
Other adjustments 
desirable.
Must exclude early 
infant deaths or 
those who unable 
to initiate 
breastfeeding 
early.
Assessed exposure 
within 30 days of 
birth and prior to 
outcome 
Assessed exposure 
more than 30 days 
after birth or after 
outcome occurred
Population-based 
recruitment
Cross-sectional 
recruitment
- -
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<0.05 or I2 values >50% were considered to represent substantial heterogeneity. All analyses 
were done using STATA 14 software. 
 
We planned to use stratified meta-analyses to explore potential sources of heterogeneity on the 
association between breastfeeding initiation and infant mortality and morbidity. We defined the 
following subgroups a priori: study quality (comparing high quality studies to low and medium 
quality studies); low birthweight (<2500 g) compared to normal birthweight infants; exclusively 
breastfed in the neonatal period compared to not exclusively breastfed infants (including partial 
and predominant breastfeeding); high income countries (HIC) compared to low- and middle-
income countries (LMIC) (as defined by the World Bank; and HIV-exposed infants compared to 
HIV-unexposed infants.  
 
 
RESULTS 
We found a total of 4825 records.  After removing 1317 duplicates, we screened 3508 titles and 
abstracts. 184 papers were selected for full text screening (Figure 2.1). A total of 22 papers were 
eligible for inclusion in the analysis [7-11, 15, 20-35] (Appendix 2, Supplemental Table 2A). 
Three papers referred to the same study and study population [25-27], and they were 
subsequently considered as one study, “Edmond 2006”. One paper contained pooled data from 
three studies [15], and we requested study-specific estimates from the authors so that each site 
could be included individually [12-14].  One study was categorised as high quality [35], seven 
studies were considered of moderate quality [9, 12-15, 27, 30-33], and 12 studies were 
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Figure 2.1. Search results
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considered low or very low quality  [7, 8, 10, 11, 20-24, 28, 29, 34] (Appendix 2, Supplemental 
Table 2B).  
 
We identified 11 studies which examined breastfeeding initiation time and neonatal mortality [9, 
10, 12-15, 20, 21, 27, 30, 33, 34] (Table 2.2). We pooled five of these studies which examined 
the association between delayed breastfeeding initiation (2-23 hours or >24 hours) compared to 
very early initiation (<1 hour) on neonatal mortality, including a total of 136,047 infants [12-15, 
27, 33]. There was evidence of a dose response relationship; increasing delay in breastfeeding 
initiation time was associated with an increasing risk of neonatal mortality. Infants who initiated 
breastfeeding 2-23 hours after birth had a 33% greater risk of neonatal mortality (95% CI: 13-
56%), and infants who initiated breastfeeding >24 hours after birth were more than twice as 
likely to die during the neonatal period (pooled RR 2.19, 95% CI: 1.73-2.77) when compared to 
those who initiated breastfeeding within one hour of birth. There was no evidence of 
heterogeneity of effect (Figure 2.2). All pooled studies were categorised as ‘moderate’ quality. In 
a sensitivity analysis, we included estimates from Garcia et al. 2011 [30], which defined ‘early 
initiation’ as breastfeeding initiation <12 hours, and we found similar results (Appendix 2 - 
Figure 2A).   
 
Six studies examined the association between breastfeeding initiation within 24 hours compared 
to >24 hours on neonatal mortality, including a total of 142,729 infants [12-15, 27, 30, 33]. In the 
largest cohorts relatively few infants initiated breastfeeding after 24 hours: 302 infants in Ghana, 
236 infants in Tanzania, and 4,039 infants in India. Infants who initiated breastfeeding more than 
24 hours after birth had a 70% greater risk of neonatal mortality compared to infants who 
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Study N Study Design Exposure Definition Effect Estimate (95% CI) Quality
Neovita (India) 44,984 Prospective Cohort
Early (<1 hr)* vs. Late (2-23, >24 hrs) 
breastfeeding initiation
aRR(2-23 hrs): 1.18 (0.93-1.49)
aRR(>24 hrs): 1.61 (1.11-2.35)
Moderate
Neovita (Ghana) 22,955 Prospective Cohort
Early (<1 hr)* vs. Late (2-23, >24 hrs) 
breastfeeding initiation
aRR(2-23 hrs): 1.41 (1.01-1.98)
aRR(>24 hrs): 3.68 (1.82-7.46)
Moderate
Neovita (Tanzania) 31,999 Prospective Cohort
Early (<1 hr)* vs. Late (2-23, >24 hrs) 
breastfeeding initiation
aRR(2-23 hrs): 1.61 (1.06-2.44) 
aRR(>24 hrs): 1.90 (0.47-7.62)
Moderate
Akter 2015 3,190 Cross-sectional
Early (<1 hr) vs. Late* (>1 hr) 
breastfeeding initiation
aOR: 0.86 (0.41-1.82) Very Low
Shah 2014 6,399
Prospective Cohort. Preterm 
infants only.
Early (<1 hr) vs. Late* (>1 hr) 
breastfeeding initiation
aRR: 0.7 (: 0.6-1.0) Moderate
Sutan 2014 500
Case Control. Low 
birthweight infants only.
Early (<1 hr)* vs. Late (>1 hr) 
breastfeeding initiation
aOR: 2.03 (: 1.09-3.90) Very Low
Niswade 2011 1087
Prospective Cohort. Tribal 
infants only.
Early* vs. Late 
breastfeeding initiation
aOR (tribal): 3.1 (05% CI:0.9-10.1) Very Low
Garcia 2011 10,352 Prospective Cohort
Early (<12 hr)* vs. Late (12-23, >24 hrs) 
breastfeeding initiation
aRR(12-24 hrs): 0.93 (: 0.59-1.46)
aRR (>24 hrs): 1.76 (: 1.01-3.07)
Moderate
Edmond 2006 10,942 Prospective Cohort
Early (<1 hr)* vs. Late (2-23 hrs, Day 2, Day 
3, >Day 4) 
breastfeeding initiation
aOR(Day1): 1.45 (0.90-2.35)
aOR(Day2): 2.70 (1.70-4.3)
aOR(Day3): 3.01 (1.70-5.38)
aOR(>Day4): 4.42 (1.76-11.09)
Moderate
Bamji 2008 4,357 Case Control
Early (Day 1) vs. Late (Day 2, >Day 3)
breastfeeding initiation
OR(Day2): 1.58 (0.17-14.51)
OR(>Day3): 10.14 (3.17-32.42)
Very Low
Mullany 2008 22,838 Prospective Cohort
Early (<1 hr)* vs. Late (2-23 hrs, Day 2, Day 
3, >Day 4) 
breastfeeding initiation
aOR(Day1): 1.43 (0.52-3.89)
aOR(Day2): 1.78 (0.64-5.00)
aOR(Day3): 2.43 (0.86-6.90)
aOR(>Day4): 2.06 (0.62-6.82)
Moderate
Table 2.2. Summary of studies of the association between early breastfeeding initiation and neonatal mortality. (*Reference group)
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Figure 2.2. Forest Plot of the relative risk of neonatal mortality (excluding deaths in the first 2-4 
days) for infants who initiated breastfeeding 2-23 hours or >24 hours after birth, compared to 
those who initiated breastfeeding early (<1 hour).
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initiated breastfeeding  within 24 hours after birth  (pooled RR 1.70, 95% CI: 1.44-2.01) (Figure 
2.3). There was no evidence of substantial heterogeneity of effect (X2 p value=0.13, I2=41 %).   
 
It was only possible to examine the association between very early initiation (<1 hour) and 
neonatal mortality among exclusively breastfed infants in three studies [12-14], and pooled 
estimates including these three cohorts have previously been published [15]. However, there 
were five studies which examined the relationship between breastfeeding initiation >24 hours 
compared to <24 hours and neonatal mortality among exclusively breastfed infants. The effect 
size was incalculable in the large India site [12], as there were no deaths among the small group 
of infants initiating breastfeeding >24 hours (n=150). Thus, we pooled the estimates from four 
studies, including a total of 65,215 infants [13-15, 27, 33]. Infants who were exclusively 
breastfed in the neonatal period who delayed breastfeeding initiation 24 hours or more after birth 
had an 85% increased risk of neonatal mortality compared to infants who initiated breastfeeding 
early (<24 hours after birth) (pooled RR 1.85, 95% CI: 1.29-2.67) (Figure 2.3). There was no 
evidence of heterogeneity of effect (X2 p value=0.21, I2=33%).   
 
The same five studies included data which allowed examination of the relationship between 
delayed breastfeeding initiation (>24 hours) compared to <24 hours and neonatal mortality 
among low birth weight infants. However, the effect was incalculable in the Tanzania site [14] as 
there were no deaths among the small group of low birthweight infants initiating breastfeeding 
after 24 hours (n=35). Thus, we pooled the estimates from four studies, including a total of 
21,258 infants [12, 13, 15, 27, 33].  Low birthweight infants who initiated breastfeeding more 
than 24 hours after birth had a 73% greater risk of neonatal mortality compared to infants who 
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Figure 2.3. Forest Plot of the relative risk of neonatal mortality (excluding deaths in the first 2-4 
days) for infants who initiated breastfeeding >24 hours after birth, compared to those who 
initiated breastfeeding early (<24 hours) for i) all infants, ii) among exclusively breastfed infants, 
iii) among low birthweight infants.
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initiated breastfeeding  <24 hours after birth  (pooled RR 1.73, 95%CI: 1.38-2.18) (Figure 2.3). 
There was no evidence of heterogeneity of effect (X2 p value=0.29, I2=20%).   
 
We were unable to perform other subgroup analyses (e.g. by quality score; high-, middle-, or 
low-income status of country; maternal HIV status; etc.) as there were less than two studies in 
each subgroup strata. Only one study (including the three neonatal vitamin A trial cohorts) 
presented effect estimates for early infant mortality (one to three months and three to six months) 
[15], and no studies presented effect estimates for infant mortality through 12 months.   
 
Table 2.3 summarizes the combined evidence regarding the association between delayed 
breastfeeding initiation and neonatal mortality. The overall quality of the evidence illustrating an 
increased risk of death among infants that initiate breastfeeding more than one hour after birth is 
rated as “high” quality. Although the pooled effect size is based on observational studies, the 
quality rating was upgraded because there is an apparent dose response relationship and a large 
increased risk of death (RR >2.0) for infants initiating >24 hours after birth. The other analyses 
that compared the risk of neonatal mortality for those initiationg breastfeeding >24 hours after 
birth to those initiating <24 hours after birth among all infants, exclusively breastfed infants, and 
low birthweight infants, were classified as “moderate” in overall quality.  The evidence is based 
on high-quality observational studies (which are considered to be “moderate” in quality due to 
the inherent limitations of observational studies), and the quality was not upgraded because a 
potential dose response relationship is not examined and the pooled relative risks are less than 
two.
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Assumed risk
1
Early 
Breastfeeding
Corresponding risk
2
Delayed
Breastfeeding
All infants, who 
ever initiated 
breastfeeding, 
surviving 2-4 days
<1 Hour: 
5.2 per 1000
2-23 Hours:
6.9 per 1000
(5.9 to 8.1)
>24 Hours:
11.4 per 1000
(9.0 to 14.4)
(2-23 Hours):
1.33 (1.13-1.56)
(>24 Hours):
2.19 (1.73-2.77)
136,047 
(5 studies)
High
4
All infants, who 
ever initiated 
breastfeeding, 
surviving 2-4 days
<24 Hours:
7.7 per 1000
>24 Hours:
13.1 per 1000
(11.1 to 15.5)
1.70 (1.44-2.01)
142,729 
(6 studies)
Moderate
5
Exclusively 
breastfeeding 
infants, who ever 
initiated 
breastfeeding, 
surviving 2-4 days
<24 Hours:
6.9 per 1000
>24 Hours:
12.4 per 1000
(8.9 to 18.4)
1.85 (1.29-2.67)
65,215  
(4 studies)
Moderate
5
Low birthweight 
infants, who ever 
initiated 
breastfeeding, 
surviving 2-4 days
<24 Hours:
18.0 per 1000
>24 Hours:
31.1 per 1000
(24.8 to 39.2)
1.73 (1.38-2.18)
21,258 
(4 studies)
Moderate
5
Table 2.3. Summary of findings regarding the association between delayed breastfeeding association and neonatal mortality
1
 The assumed risk is the median risk in the 'early breastfeeding' group across all studies providing this information.
2
 The corresponding risk is based on the assumed risk in the 'early breastfeeding' group and the relative effect of the intervention (and its 95% 
confidence interval).
4
 All five studies are categorized as having a moderate risk of bias, but the overall strength of evidence is upgrade to 'High' because the studies are 
consistent, there is a large effect size (RR >2), and there is evidence dose response.
5
 All studies are categorized as having a moderate risk of bias. There is no evidence of dose response (due to study design) and there is no large 
effect size.
Illustrative comparative risks (95% CI)
Neonatal 
Mortality
Number of 
participants 
(studies)
Quality of the 
evidence 
(GRADE)
3
Relative effect 
(95% CI)
PopulationOutcome
3
GRADE Working Group grades of evidence description [17]: High quality: Further research is very unlikely to change our confidence in the estimate 
of effect.; Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the 
estimate.; Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change 
the estimate.; Very low quality: We are very uncertain about the estimate.
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All six studies of timing of breastfeeding initiation and nutritional status (e.g. stunting, wasting, 
underweight, or early weight loss) were considered very low quality. We could not pool any of 
the estimates due to variations in the exposure definition or the time period of outcome 
assessment (Table 2.4). One cross-sectional study from Guatemala observed 67% increased risk 
of stunting and more than threefold increased risk of being underweight among infants age <46 
days who initiated breastfeeding after one hour of birth compared to infants who initiated 
breastfeeding within one hour of birth [11]. Two other studies found no relationship between 
breastfeeding initiation and the risk of stunting or underweight [8, 28]. None of the three cross-
sectional studies which assessed wasting found a relationship with breastfeeding initiation time 
[8, 11, 28]. Similarly, there was no observed relationship between breastfeeding initiation time 
and early weight loss in three studies [22, 24, 29]. 
 
There were five studies which examined the relationship between timing of breastfeeding 
initiation on morbidity (e.g. diarrhea, respiratory infections, hypothermia, and umbilical cord 
infection) with mixed quality levels (Table 2.5). We were unable to pool any of the morbidity 
studies due to differences in exposure definition, time of outcome assessment, or difference in 
type of effect estimate (Table 2.5). Two studies showed a reduced risk of diarrhea among infants 
aged <6 months associated with early breastfeeding initiation (within three days after birth [23] 
or within one hour [7]). Mullany and colleagues reported an association between delayed 
breastfeeding and an increased risk of umbilical cord infection among infants in Tanzania [31] 
and an increased risk of hypothermia among infants in Nepal [32]. Similarly, Van den Bosch 
reported a two-fold greater  risk of hypothermia among infants randomized to “mother’s choice 
 51 
 
Table 2.4. Summary of studies of the association between early breastfeeding initiation and nutrition outcomes. (*Reference group)
Malnutrition (Stunting / HAZ)
Study Sample Size Study Design Exposure Definition
Outcome 
Definition
Effect Estimate Quality
Wren 
2015
190 Cross-Sectional
Early (<1 hr)* vs. Late (>1 hr) 
breastfeeding initiation
 HAZ < –2 SD
at <46 days
RR: 1.67 (95% CI: 1.15-2.43) Very Low
Meshram 
2012
351 Cross-Sectional
Early (<1 hr)* vs. Late (>1 hr) 
breastfeeding initiation
 HAZ < –2 SD 
at 1 year
RR: 1.19 (95% CI: 0.63-2.26) Very Low
Engebretsen 
2008
723 Cross-Sectional
Early (<2 hrs)* vs. Late (2-24 hrs, >24 hrs)
breastfeeding initiation
 HAZ < –2 SD
at <1 year
OR: (2-24 hrs): 1.06 (95% CI: 0.56-1.99)
OR: (>24 hrs): 1.27 (95% CI: 0.80-2.03)
Very Low
Malnutrition (Wasting / WHZ)
Wren 
2015
190 Cross-Sectional
Early (<1 hr)* vs. Late (>1 hr) 
breastfeeding initiation
WHZ < –2 SD
at <46 days
RR: 0.84 (95% CI: 0.14-4.88) Very Low
Meshram 
2012
351 Cross-Sectional
Early (<1 hr)* vs. Late (>1 hr) 
breastfeeding initiation
 WHZ < –2 SD 
at 1 year
RR: 0.85 (95% CI: 0.52-1.38) Very Low
Engebretsen 
2008
723 Cross-Sectional
Early (<2 hrs)* vs. Late (2-24 hrs, >24 hrs) 
breastfeeding initiation
 WHZ < –2 SD
at <1 year
OR: (2-24 hrs): 1.07 (95% CI: 0.39-2.92)
OR: (>24 hrs): 0.81 (95% CI: 0.33-2.06)
Very Low
Malnutrition (Underweight / WAZ)
Wren 
2015
190 Cross-Sectional
Early (<1 hr)* vs. Late (>1 hr) 
breastfeeding initiation
 WAZ < –2 SD
at <46 days
RR: 3.06 (95% CI: 1.49-6.29) Very Low
Meshram 
2012
351 Cross-Sectional
Early (<1 hr)* vs. Late (>1 hr) 
breastfeeding initiation
 WAZ < –2 SD 
at 1 year
RR: 0.87 (95% CI: 0.59-1.28) Very Low
Malnutrition (Early weight loss)
Dewey 
2003
280
Prospective 
Cohort
Early (<1 hr) vs. Late (>1 hr) 
breastfeeding initiation
Weight loss >10% 
since birth at 3 days
RR: 1.20 (95% CI: 0.62-2.33) Very Low
Caglar 
2006
90 Case-Control
Mean time to first 
breastfeeding (hrs)
Weight loss >10% 
since birth at 4-9 days
Weight loss >10% group: 3.89 hrs (SE 2.37) 
Weight loss <10% group: 2.14 hrs (SE 1.31)
Very Low
Enzunga 
1990
330
Prospective 
Cohort
Time of breastfeeding initiation (hrs)
Weight loss since 
birth
Time of breastfeeding initiation and weight 
loss were associated in univariate and 
multiavriate linear regression
Very Low
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Table 2.5. Summary of studies of the association between early breastfeeding initiation and morbidity outcomes (*Reference group)
Diarrhea
Study Sample Size Study Design Exposure Definition
Outcome 
Definition
Effect Estimate Quality
Clemmens 
1999
198
Prospective 
Cohort
Early (<3 days) vs. Late (>3 days)* 
breastfeeding initiation
Diarrhea 
at <6 months
aRR: 0.74 (95% CI: 0.56-0.98) Low
Clemmens 
1999
198
Prospective 
Cohort
Early (<3 days) vs. Late (>3 days)* 
breastfeeding initiation
Diarrhea
at 6-12 months
aRR: 0.95 (95% CI: 0.70-1.31) Low
Hajeebhoy 
2014
6068 Cross-Sectional
Early (<1 hr) vs. Late (>1 hr)* 
breastfeeding initiation
Diarrhea
at <6 months
aOR:  0.74 (95% CI:0.58-0.93) Very low
ARI
Hajeebhoy 
2014
6068 Cross-Sectional
Early (<1 hr) vs. Late (>1 hr)* 
breastfeeding initiation
ARI
at <6 months
aRR: 0.91 (95% CI: 0.80-1.03) Very low
Hypothermia
Mullany 
2010
19180
Prospective 
Cohort
Early (<24 hrs)* vs. Late (>24 hrs) 
breastfeeding initiation
Prevalence of 
axillary
measures <35.0°C 
at <28 days
aRR: 1.19 (95% CI: 1.08-1.30) Moderate
Van den Bosch 
1990
160
Randomized 
Trial
Immediate* vs. Mother's choice of 
breastfeeding initiation time.
Rectal temperatue 
<36.5°C at 2, 4, and 
~24 hrs after birth
RR: 2.45 (95% CI: 1.36-4.41) High
Umbilical Cord Infection
Mullany 
2009
1653
Prospective 
Cohort
Early (<1 hr) vs. Late (>1 hr)* 
breastfeeding initiation
1. Pus with any 
redness (Broad)
2. Moderate or 
severe redness 
(Restrictive)
1. aRR: 0.74 (95% CI: 0.38-1.47)
2. aRR: 0.29 (95% CI: 0.11-0.74)
Moderate
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of breastfeeding initiation time” compared to those randomized to immediate breastfeeding 
initiation in Malawi [35]. 
 
 
DISCUSSION  
 
Our review provides new insight on the increased risk of neonatal mortality associated with 
delayed breastfeeding initiation (defined in this review as initiation after the first hour after 
birth). We demonstrated a clear dose-response relationship; the risk of neonatal mortality 
increased with increased delay in breastfeeding initiation. Infants who initiated breastfeeding 
between 2-23 hours after birth had a 33% greater risk of neonatal mortality compared to infants 
who initiated breastfeeding within an hour of birth. Neonatal mortality risk was more than 100% 
greater in infants who initiated breastfeeding more than 24 hours after birth. Our findings are 
based on five prospective cohort studies of 136,047 breastfed, live born infants who survived the 
first two to four days of life.  
 
The intervention of interest (i.e. early breastfeeding initiation) has been inconsistently defined 
across studies. Some authors define “early breastfeeding initiation” as breastfeeding within one 
hour of birth (as we do here); others define early initiation as “within three days of birth” [23]. 
Two previously published meta-analyses defined early breastfeeding initiation as initiation 
within 24 hours of birth [4, 5]. However, in our three largest cohorts, accounting for nearly 
100,000 infants [12-15], very few mothers initiated breastfeeding after 24 hours (n=4,577). In 
addition, the World Health Organization (WHO) and the United Nations Children’s Fund 
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[UNICEF] recommend that breastfeeding is initiated within an hour of birth. Thus, we proposed 
that the primary intervention of interest for this study should be the effect of breastfeeding 
initiation within an hour of birth (i.e. very early breastfeeding initiation). Using this definition of 
“very early breastfeeding initiation”, we pooled effect estimates for all-cause neonatal mortality 
for more than 136,000 infants enrolled in prospective cohorts in Ghana, India, Nepal, and 
Tanzania [12-15, 27, 33]. Similar effects were demonstrated after pooling the six studies [12-15, 
27, 30, 33] which assessed the effect of breastfeeding initiation <24 hours. We found that early 
initiation of breastfeeding was beneficial, with a very similar effect size, even when the analysis 
was restricted to low birth weight infants. Due to the higher baseline risk of death among low 
birthweight infants, large gains in the number of deaths averted may be achieved through very 
early breastfeeding initiation in this group. 
 
We also found that early initiation of breastfeeding was similarly beneficial, even when the 
analysis was restricted to exclusively breastfed infants. We have previously reported a similar 
finding regarding the effect of breastfeeding initiation within an hour of birth on neonatal 
mortality in exclusively breastfed infants using pooled data from nearly 100,000 infants enrolled 
in neonatal vitamin A supplementation trials [15].  This pooled analysis demonstrated a strong 
protective effect of very early breastfeeding initiation (within one hour of life) among infants 
who were exclusively breastfed in the neonatal period, at one month, and at three months of life 
[15]. This systematic review and meta-analysis found there was no additional data to pool 
beyond that provided by the neonatal vitamin A supplementation trials, as no other studies 
examined the effect of very early breastfeeding (within one hour) in exclusively breastfed 
infants. However, we updated the meta-analysis regarding early initiation of breastfeeding 
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(within 24 hours) among exclusively breastfed infants, though we were unable to include the 
largest cohort (Mazunder 2015) as the number of exclusively breastfed infants who initiated 
breastfeeding more than 24 hours after birth was very small. The pooled results of four studies 
(including 65,215 infants) showed that initiation of breastfeeding after the first 24 hours of life 
was associated with an 85% increased risk of neonatal mortality compared to infants who 
initiated breastfeeding within 24 hours after birth, and there was no evidence of heterogeneity of 
effect. We previously postulated that early initiation of breastfeeding independently reduces 
neonatal and early infant mortality by specific biological mechanisms, in addition to increasing 
rates of exclusive breastfeeding [15]. Our new meta-analysis provides additional evidence to 
support this hypothesis. This is in contrast to the previous meta-analysis which reported that 
there was no association between early breastfeeding (within 24 hours) and all-cause neonatal 
mortality among those that were exclusively breastfed [4].  However, as noted by Debes et al, 
there was limited data available to examine the exclusively breastfed subgroup at that time.  
 
We identified five studies which examined the effect of early breastfeeding initiation on 
morbidity (e.g. diarrhea, respiratory infections, hypothermia, and umbilical cord infection) [7, 
23, 31, 32, 35], and there were six studies that examined nutrition outcomes [8, 11, 22, 24, 28, 
29]. However, most papers had a ‘low’ or ‘very low’ quality score, and we were unable to pool 
the study-specific estimates due to differences in the exposure definition, time of outcome 
assessment, or type of published effect estimate. Additional, higher quality research is needed to 
understand the relationship between early breastfeeding initiation and infant morbidity and 
nutrition outcomes. 
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Our findings have important implications for prioritizing interventions to improve neonatal 
survival. There is a strong biological basis for the survival benefits associated with early 
breastfeeding. Early breastfeeding initiation exposes the infant to maternal colostrum, which is 
thought to decrease the risk of microbial translocation, accelerate intestinal maturation, and 
promote resistance and epithelial recovery from infection [7-9]. Early breastfeeding may also 
reduce hypothermia and foster attachment and bonding through close contact with the mother 
[9]. Based on our review of the evidence, we recommend that early initiation of breastfeeding 
should be considered when estimating the overall survival benefits of breastfeeding, and should 
be considered for inclusion in models that assess the benefits of interventions for infant survival, 
such as those used in the Lives Saved Tool (LiST) [18].  
 
There are several strengths of this systematic review and meta-analysis. First, we conducted a 
thorough review of the literature using all appropriate search engines, without limitations based 
on date of publication. For all outcomes, we provided a narrative synthesis of the evidence to 
account for the heterogeneity of exposure definition. Finally, the meta-analysis of the effect of 
breastfeeding initiation and all-cause infant mortality is based on large cohorts nested within 
well-conducted, population-based, randomized control trials, and we analysed the data to 
demonstrate the strength of a dose-response relationship. Our review and meta-analysis also had 
several limitations. We were unable to perform subgroup analyses by quality score, income 
status of country, or maternal HIV status as there were insufficient studies in these subgroups. 
Three studies [12-14], which have previously published pooled estimates [15], presented effect 
estimates for infant mortality between one to three months and three to six months, and no 
studies presented effect estimates for infant mortality through 12 months. The review was also 
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based entirely on observational data. However, a randomized trial of this intervention would not 
be considered ethical, so we must rely on methodologically robust analysis of high quality 
observational data.  Additional research among high quality, prospective cohorts regarding the 
relationship between early breastfeeding initiation and cause-specific mortality and severe 
morbidity would strengthen the overall quality of the evidence. 
 
Our study suggests that the effects of early breastfeeding initiation should be taken into account 
when policy frameworks or models such as LiST are applied to estimate the survival benefits of 
breastfeeding. Breastfeeding promotion programs which can remove structural, cultural, and 
information barriers to promote breastfeeding should also emphasize the importance of early 
initiation of breastfeeding, in addition to promoting exclusive breastfeeding. Furthermore, health 
facility policies and health provider knowledge can promote early breastfeeding initiation. This 
is particularly relevant for countries, where neonatal and infant mortality rates are high, most 
women already exclusively or predominantly breastfeed their infants, and delayed initiation of 
breastfeeding beyond the first hour of life is common.  
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Appendix 1 
Specific Search Strategy 
 
Database: PubMed 
Date of Search: 2015-12-09 
Results: 2112 Records 
Search Strategy: 
("Breast Feeding"[Mesh] OR breast fe*[tiab] OR breastfe*[tiab]) 
AND  
("Time Factors"[mesh] OR initiat*[tiab] OR timing[tiab] OR delay*[tiab] OR start[tiab] OR starting[tiab] 
OR starts[tiab] OR started[tiab] OR early breast* OR early suckl*[tiab]) 
 AND  
("Infant Mortality"[Mesh] OR "Infant Death"[Mesh] OR "Perinatal Death"[Mesh] OR 
"mortality"[Subheading] OR "Survival"[Mesh] OR mortality[tiab] OR death*[tiab] OR died[tiab] OR 
survival[tiab] OR "Diarrhea"[Mesh] OR diarrhea*[tiab] OR diarrhoea*[tiab] OR "Respiratory Tract 
Infections"[Mesh] OR respiratory infect*[tiab] OR respiratory illness*[tiab] OR respiratory disease*[tiab] 
OR respiratory tract infect*[tiab] OR influenza[tiab] OR pneumonia[tiab] OR bronchitis[tiab] OR 
"Sepsis"[Mesh] OR sepsis[tiab] OR septic[tiab] OR bacteremia[tiab] OR septicemi*[tiab] OR 
("Umbilical Cord"[mesh] AND "Bacterial Infections and Mycoses"[Mesh]) OR omphalitis[tiab] OR 
umbilical cord infection*[tiab] OR "Hospitalization"[Mesh] OR hospitali*[tiab] OR hospital 
admission*[tiab] OR "Malnutrition"[Mesh] OR "Infant Nutrition Disorders"[Mesh] OR "Child Nutrition 
Disorders"[Mesh] OR "Wasting Syndrome"[Mesh:noexp] OR "Weight Gain"[mesh] OR "Weight 
Loss"[mesh] OR malnutri*[tiab] OR malnourish*[tiab] OR mal nutri*[tiab] OR under nourish*[tiab] OR 
undernutrition[tiab] OR under nutrition[tiab] OR nutritional status[tiab] OR weight gain[tiab] OR weight 
loss[tiab] OR underweight[tiab] OR under weight[tiab] OR growth failure[tiab] OR marasmus[tiab] OR 
kwashiorkor[tiab] OR stunt*[tiab] OR wasting[tiab] OR weight for age[tiab] OR length for age[tiab] OR 
weight for length[tiab]) 
 AND  
("Infant"[Mesh] OR "Child, Preschool"[Mesh] OR infant*[tiab] OR new born*[tiab] OR newborn*[tiab] 
OR neonat*[tiab] OR baby[tiab] OR babies[tiab] OR child*[tiab]) 
 
Database: Embase 
Date of Search: 2015-12-09 
Results: 684 Records 
Search Strategy: 
(('breast feeding'/exp AND 'time'/exp) OR (('breast fed' OR 'breast feed' OR 'breast feeds' OR 'breast 
feeding' OR breastfe* OR suckl*) NEAR/3 (initiat* OR timing OR delay* OR start OR starting OR starts 
OR started OR early OR immediate OR beginning)):ab,ti) 
AND 
('infant mortality'/exp OR 'newborn death'/exp  OR 'perinatal death'/exp OR 'perinatal mortality'/exp OR 
'survival'/exp OR mortality:ab,ti OR death*:ab,ti OR died:ab,ti OR survival:ab,ti OR 'infantile 
diarrhea'/exp OR diarrhea*:ab,ti OR diarrhoea*:ab,ti OR 'respiratory tract infection'/exp OR (respiratory 
NEAR/3 (infect* OR illness* OR disease*)):ab,ti OR influenza:ab,ti OR pneumonia:ab,ti OR 
bronchitis:ab,ti OR 'newborn sepsis'/exp OR sepsis:ab,ti OR septic:ab,ti OR bacteremia:ab,ti OR 
septicemi*:ab,ti OR 'omphalitis'/exp OR omphalitis:ab,ti OR (('umbilical cord' OR umbilicus) NEAR/3 
infection*):ab,ti OR 'child hospitalization'/exp OR hospitali*:ab,ti OR (hospital NEAR/3 
admission*):ab,ti OR 'malnutrition'/exp OR 'nutritional deficiency'/exp OR 'wasting syndrome'/exp OR 
'weight gain'/exp OR 'weight loss'/exp OR malnutri*:ab,ti OR malnourish*:ab,ti OR undernourish*:ab,ti 
OR (mal NEXT/1 nutri*):ab,ti OR (under NEXT/1 nourish*):ab,ti OR undernutrition:ab,ti OR 'under 
nutrition':ab,ti OR 'nutritional status':ab,ti OR 'weight gain':ab,ti OR 'weight loss':ab,ti OR 
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underweight:ab,ti OR 'under weight':ab,ti OR 'growth failure':ab,ti OR marasmus:ab,ti OR 
kwashiorkor:ab,ti OR stunt*:ab,ti OR wasting:ab,ti OR 'weight for age':ab,ti OR 'length for age':ab,ti OR 
'weight for length':ab,ti) 
AND 
('infant'/exp OR 'preschool child'/exp OR infant*:ab,ti OR (new NEXT/1 born*):ab,ti OR newborn*:ab,ti 
OR neonat*:ab,ti OR baby:ab,ti OR babies:ab,ti OR child*:ab,ti) 
 
Database: Web of Science 
Science Citation Index Expanded (SCI-EXPANDED) --1900-present 
Social Sciences Citation Index (SSCI) --1900-present 
Conference Proceedings Citation Index- Science (CPCI-S) --1990-present 
Conference Proceedings Citation Index- Social Science & Humanities (CPCI-SSH) --1990-present  
Date of Search: 2015-12-10 
Results: 696 Records 
Search Strategy: 
TS=(("breast fed" OR "breast feed" OR "breast feeds" OR "breast feeding" OR "breastfe*" OR "suckl*") 
NEAR/3 ("initiat*" OR "timing" OR "delay*" OR "start" OR "starting" OR "starts" OR "started" OR 
"early" OR "immediate" OR "beginning")) 
AND 
TS=("mortality" OR "death*" OR "died" OR "survival" OR "diarrhea*" OR "diarrhoea*" OR 
("respiratory" NEAR/3 ("infect*" OR "illness*" OR "disease*")) OR "influenza" OR "pneumonia" OR 
"bronchitis" OR "sepsis" OR "septic" OR "bacteremia" OR "septicemi*" OR "omphalitis" OR 
(("umbilical cord" OR "umbilicus") NEAR/3 infection*) OR "hospitali*" OR ("hospital" NEAR/3 
"admission*") OR "malnutri*" OR "undernourish*" OR "mal nutri*" OR "malnourish*" OR "under 
nourish*" OR "undernutrition" OR "under nutrition" OR "nutritional status" OR "weight gain" OR 
"weight loss" OR "underweight" OR "under weight" OR "growth failure" OR "marasmus" OR 
"kwashiorkor" OR "stunt*" OR "wasting" OR "weight for age" OR "length for age" OR "weight for 
length") 
AND 
TS=("infant*" OR "new born*" OR "newborn*" OR "neonat*" OR "baby" OR "babies" OR "child*") 
 
Database: CINAHL  
Date of Search: 2015-12-10 
Results: 327 Records  
Search Strategy: 
(MH ("Time Factors" AND MH "Breast Feeding+") OR TI (("breast fed" OR "breast feed" OR "breast 
feeds" OR "breast feeding" OR breastfe* OR suckl*) N3 (initiat* OR timing OR delay* OR start OR 
starting OR starts OR started OR early OR immediate OR beginning)) OR AB (("breast fed" OR "breast 
feed" OR "breast feeds" OR "breast feeding" OR breastfe* OR suckl*) N3 (initiat* OR timing OR delay* 
OR start OR starting OR starts OR started OR early OR immediate OR beginning))) 
AND 
(MH ("Infant Mortality" OR "Infant Death" OR "Perinatal Death" OR "Diarrhea") OR "Diarrhea 
(NANDA)" OR "Respiratory Tract Infections+" OR "Sepsis+" OR "Hospitalization" OR "Malnutrition" 
OR "Infant Nutrition Disorders" OR "Child Nutrition Disorders" OR "Nutitional Status" OR "Nutritional 
Status (Iowa NOC)" OR "Wasting Syndrome" OR "Weight Gain" OR "Weight Loss") OR TI ("mortality" 
OR "death*" OR "died" OR "survival" OR "diarrhea*" OR "diarrhoea*" OR ("respiratory" N3 ("infect*" 
OR "illness*" OR "disease*")) OR "influenza" OR "pneumonia" OR "bronchitis" OR "sepsis" OR 
"septic" OR "bacteremia" OR "septicemi*" OR "omphalitis" OR (("umbilical cord" OR "umbilicus") N3 
infection*) OR "hospitali*" OR ("hospital" N3 "admission*") OR "malnutri*" OR "malnourish*" OR 
"undernourish*" OR "mal nutri*" OR "under nourish*" OR "undernutrition" OR "under nutrition" OR 
"nutritional status" OR "weight gain" OR "weight loss" OR "underweight" OR "under weight" OR 
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"growth failure" OR "marasmus" OR "kwashiorkor" OR "stunt*" OR "wasting" OR "weight for age" OR 
"length for age" OR "weight for length") OR AB ("mortality" OR "death*" OR "died" OR "survival" OR 
"diarrhea*" OR "diarrhoea*" OR ("respiratory" N3 ("infect*" OR "illness*")) OR "influenza" OR 
"pneumonia" OR "bronchitis" OR "sepsis" OR "septic" OR "bacteremia" OR "septicemi*" OR 
"omphalitis" OR (("umbilical cord" OR "umbilicus") N3 infection*) OR "hospitali*" OR ("hospital" N3 
"admission*") OR "malnutri*" OR "malnourish*" OR "undernourish*" OR "mal nutri*" OR "under 
nourish*" OR "undernutrition" OR "under nutrition" OR "nutritional status" OR "weight gain" OR 
"weight loss" OR "underweight" OR "under weight" OR "growth failure" OR "marasmus" OR 
"kwashiorkor" OR "stunt*" OR "wasting" OR "weight for age" OR "length for age" OR "weight for 
length")) 
AND 
((MH "Infant+" OR "Child, Preschool") OR TI ("infant*" OR "new born*" OR "newborn*" OR 
"neonat*" OR "baby" OR "babies" OR "child*") OR AB ("infant*" OR "new born*" OR "newborn*" OR 
"neonat*" OR "baby" OR "babies" OR "child*")) 
 
Database: POPLINE 
Date of Search: 2015-12-17 
Results: 744 Records 
Note: Acknowledgements for assistance with running this search to Debra L. Dickson | POPLINE 
Manager | Knowledge for Health (K4Health) Johns Hopkins Center for Communication Programs (CCP), 
111 Market Place, Suite 310, Baltimore, MD 21202 ddickson@jhuccp.org | www.popline.org | 410-659-
6300 
Search Strategy: 
 
("breast feed" OR "breast feeds" OR "breast feeding" OR "breast fed" OR breastfe*) 
AND  
(initiation OR initiate* OR initiating OR timing OR delay*) 
AND 
(mortality OR death* OR died OR survival OR diarrhea* OR diarrhoea* OR "respiratory infection" OR 
"respiratory illness" OR "respiratory disease" OR "respiratory infections" OR "respiratory illnesses" OR 
"respiratory diseases" OR influenza OR pneumonia OR bronchitis OR sepsis OR septic OR bacteremia 
OR septicemi* OR omphalitis OR "umbilical cord infection" OR hospitali* OR "hospital admission" OR 
"hospital admissions" OR malnutri* OR malnourish* OR undernourish* OR undernutrition OR 
"nutritional status" OR "weight gain" OR "weight loss" OR underweight OR "under weight" OR "growth 
failure" OR marasmus OR kwashiorkor OR stunt* OR wasting OR "weight for age" OR "length for age" 
OR "weight for length") 
AND 
(infant* OR newborn* OR neonat* OR baby OR babies OR child*) 
 
Database: LILACS 
Date of Search: 2015-12-15 
Results: 177 Records  
Search Strategy: 
 
((breast AND feed$) OR breastfe$ OR amamantamiento OR (aleitamento AND materno)) 
AND  
(initiat$ OR timing OR delay$ OR inicia$ OR atrasar OR atraso OR retrasar OR retraso) 
AND 
(mortality OR death$ OR died OR survival OR diarrhea$ OR diarrhoea$ OR (respiratory AND 
(infection$ OR illnes$ OR disease&)) OR influenza OR pneumonia OR bronchitis OR sepsis OR septic 
OR bacteremia OR septicemi$ OR omphalitis OR hospitali$ OR (hospital AND admission$) OR 
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malnutri$ OR undernurish$ OR undernutrition OR marasmus OR kwashiorkor OR stunt$ OR wasting OR 
(weight AND (loss OR gain OR age OR length)) OR mortalida$ OR muerte OR supervivencia OR 
sobrevivencia OR diarrea OR ((infección$ OR enfermedad$) AND irespiratoria$) OR neumonía OR 
bronquitis OR septicemia OR onfalitis OR (ingres$ AND hospitalar$) OR desnutri$ OR ((aumento OR 
pérdida OR cambio OR bajo) AND peso) OR debilitante OR morte OR sobrevivência OR diarréia OR 
((doença$ OR infecção) AND respiratóri$) OR gripe OR bronquite OR sepsia OR hospitalização OR 
((Admiss$ OR internaç$) AND hospitalar$) OR subnutrição OR ((ganho OR perda OR mudança OR 
baixo OR abaixo OR idade OR comprimento) AND peso) OR nanismo OR desperdiçando) 
AND  
(infant$ OR newborn$ OR neonat$ OR baby OR babies OR child$ OR niño OR niños OR bebé OR bebés 
OR ((recién OR recém) AND nascido$) OR criança$) 
 
Database: AIM 
Date of Search: 2015-12-15 
Results: 6 Records 
Search Strategy: 
((breast AND feed$) OR breastfe$) AND (initiat$ OR timing OR delay$) [keywords] 
 
 
Database: Index Medicus for the Eastern Mediterranean Region - IMEMR 
Date of Search: 2015-12-15 
Results: 37 Records 
Search Strategy: 
((breast AND feed$) OR breastfe$) AND (initiat$ OR timing OR delay$) [KeyWords]  
AND 
(mortality OR death$ OR died OR survival OR diarrhea$ OR diarrhoea$ OR (respiratory AND 
(infection$ OR illnes$ OR disease&)) OR influenza OR pneumonia OR bronchitis OR sepsis OR septic 
OR bacteremia OR septicemi$ OR omphalitis OR hospitali$ OR (hospital AND admission$) OR 
malnutri$ OR undernurish$ OR undernutrition OR marasmus OR kwashiorkor OR stunt$ OR wasting OR 
(weight AND (loss OR gain OR age OR length))) [KeyWords]  
 
 
Database: WPRI (Western Pacific) 
Date of Search: 2015-12-15 
Results: 37 Records  
Search Strategy: 
("breast feeding" OR breastfeeding) AND (initiation OR initiate OR initiates OR timing OR delay OR 
delays OR delayed) 
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Appendix 2 - Figure 2A. Forest Plot of the relative risk of neonatal mortality (excluding deaths 
in the first 2-4 days) for infants who initiated breastfeeding 2-23 hours or >24 hours after birth, 
compared to those who initiated breastfeeding early (<1 or <1 hour) – including Garcia 2001 
estimates.
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Appendix 2 - Table 2A. Summary of Relevant Studies 
Study Population Study Design Exposure Definition Outcomes Definitions Summary of Limitations
Quality 
Score
Akter 
2015
Bangladesh 
Demographic and 
Health Survey
Cross-
sectional
Early (<1 hr) vs. Late (>1 hr) 
breastfeeding initiation
Neonatal Mortality
Inadequate sample size (n=3190). Risk of 
selection bias due to cross-sectional 
study design. Risk of information bias 
due to long recall period (up to 3 years). 
Did not account for reverse causality.
Very low
Bamji 
2008
India: Medak 
district, Andhra 
Pradesh
Retrospective 
(1998-2001) 
and 
prospective 
(2001-03) 
cohort
Early (<24 hrs) vs. Late (>=24 
hrs) breastfeeding initiation
Neonatal Mortality
Risk of selection/attrition bias because 
30% of selected women were not 
reachable for postpartum assessment. 
Risk of information bias due to long recall 
(1-2 months after birth). Inadequate 
adjustment for confounding. Did not 
account for reverse causality. 
Very low
Caglar 
2006
Turkey: 
Gaziosmanpasa 
Medical Faculty
Case control 
Mean age at first 
breastfeeding (in hours)
Weight loss <10% No adjustment for confounding. Very low
Clemens 
1999
Egypt : Abu 
Homos district
Prospective 
cohort study 
Early (<3 days) vs. Late (>3 
days) breastfeeding 
initiation
Diarrhea Adjusted models do not include a term 
for preterm or low birthweight status.
Low
Dewey 
2003
USA: Davis, 
California
Prospective 
cohort 
Early (<1 hr) vs. Late (>1 hr) 
breastfeeding initiation
Excess weight loss at 
day 3
Inadequate adjustment for confounding. 
Did not account for reverse causality.
Very low
Edmond 
2006
Ghana: Kintampo, 
Wenchi, 
Techiman, and 
Nkoranza districts 
in the Brong 
Ahafo region
Prospective 
cohort (within 
RCT)
Early (<1 hr) vs. Late (1-24 
hr, 24-48 hr, 48-72 hr >=72 hr) 
breastfeeding iniation 
Neonatal Mortality None Moderate
Engebretsen 
2008
Uganda: Mbale 
district
Cross-
sectional 
Early (<2 hr) vs. Late (2-24 
hr, >24 hr) breastfeeding 
iniation 
Stunted (HAZ < –2 SD), 
Wasted (WHZ < –2 SD) 
Risk of selection bias. Inadequate 
adjustment for confounding. Did not 
account for reverse causality.
Very low
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Appendix 2 – Table 2A (continued). Summary of Relevant Studies
Study Population Study Design Exposure Definition Outcomes Definitions Summary of Limitations
Quality 
Score
Enzunga 
1990
Zaire: Evangelical 
Medical Centre
Prospective 
cohort
Time of breastfeeding 
initiation (hrs)
Weight loss since birth
The inclusion criteria and loss to follow 
up are not described. There is no 
information regarding assessment of 
exposure or outcome. There is no 
adjustment for confounding. Did not 
account for reverse causality.
Very low
Garcia 
2011
India: Tamil Nadu Cohort
Early (<12 hr) vs. Late (12-24 
hrs, > 24 hrs) breastfeeding 
initiation
Neonatal Mortality None Moderate
Hajeebhoy 
2014
Vietnam: 11 
provinces
Cross-
sectional
Early (<1 hr) vs. Late (>1 hr) 
breastfeeding initiation
Diarrhea 
ARI
 Risk of selection bias due to cross-
sectional study design. Risk of 
information bias due to long recall period 
(up to 3.2 months). Inadequate 
adjustment for confounding. Did not 
account for reverse causality.
Very low
Meshram 
2012
India: Medak 
district, Andhra 
Pradesh
Cross-
sectional
Early (<1 hr) vs Late (1-3 hrs, 
4-12 hrs, 13-24 hrs, >24 hrs) 
breastfeeding initiation
Stunted (HAZ < –2 SD), 
Underweight (WAZ<–2 
SD), 
Wasted (WHZ < –2 SD) 
Inadequate sample size. Risk of selection 
bias due to cross-sectional study design. 
Inadequate adjustment for confounding.
Very low
Mullany 
2008
Nepal: Sarlahi 
District
Prospective 
cohort (within 
a RCT)
Early (<1 hr) vs. Late (1-24 
hr, 24-48 hr, 48-72 hr >=72 hr) 
breastfeeding iniation 
Neonatal Mortality None Moderate
Mullany 
2010
Nepal: Sarlahi 
District
Prospective 
cohort (within 
a RCT)
Breastfeeding initiation (hrs) 
<24 hrs and >=24 hrs
Hypothermia None Moderate
Mullany 
2009
Tanzania: Pemba 
Island
Prospective 
cohort (within 
a RCT)
Early (<1 hr) vs. Late* (>1 hr) 
breastfeeding initiation
Umbilical cord infection None Moderate
Neovita 
Study Group
2016
[Includes:
Edmond 2015
Masanja 2015
Mazunder 2015]
Ghana, India, 
Tanzania: 
BrongAhafo 
Ghana, Haryana 
India, Dar es 
Salaam and 
Morogoro 
Tanzania
Prospective 
cohort (within 
3 RCTs)
Early (<1 hr) vs. Late (2-24 
hr, >24 hr) breastfeeding 
iniation 
Neonatal Mortality,
Mortality from 1-3 
months, Mortality from 
3-6 months
None Moderate
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 Appendix 2 – Table 2A (continued). Summary of Relevant Studies
Study Population Study Design Exposure Definition Outcomes Definitions Summary of Limitations
Quality 
Score
Niswade 
2011
India: Nagpur 
district
Cohort
Delayed initiation of
breastfeeding (not defined)
Neonatal Mortality Did not account for reverse causality. Very low
Shah 
2014
Bangladesh: 
Sylhet district
Prospective 
cohort (within 
RCT)
Early (<1 hr) vs. Late (>1 hr) 
breastfeeding initiation
Neonatal Mortality None Moderate
Sutan 
2014
Indonesia: Aceh 
Province
Unmatched 
case control
Early (<1 hr) vs. Late (>1 hr) 
breastfeeding initiation
Neonatal Mortality
Risk of information bias due to 
restrospective assessment of 
breastfeeding after child death. Did not 
account for reverse causality.
Very low
Van den Bosch
1990
Malawi: Kamuzu 
Central Hsopital
Randomized 
Control Trial
Early initation 
encouragement vs.  Initation 
at time of mother's choice
Hypothermia: Rectal 
temperatue <36.5°C at 2, 
4, and ~24 hrs after 
birth
None. 
Note that randomized groups were 
comparable.
High
Wren 
2015
Guatemala: Mam-
Mayan 
communities in 
the Western 
Highlands
Cross-
sectional
Early (<1 hr) vs. Late (>1 hr) 
breastfeeding initiation
Stunted (HAZ < –2 SD), 
Underweight (WAZ<–2 
SD), 
Wasted (WHZ < –2 SD) 
Inadequate sample size. Inadequate 
adjustment for confounding.
Very low
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Appendix 2 – Table 2B. Quality Assessment of Included Studies 
Study
Score for 
study design
 Risk of 
selection 
bias?
 Risk of 
information 
bias?
 Risk of 
attrition bias?
 Adequate 
adjustment 
for 
confounding?
 Accounted 
for reverse 
causality?
Should the 
score for 
study design 
be adjusted 
for study 
quality?
Score after 
adjustment
Akter 
2015
Low - Cross-
sectional
Yes - cross 
sectional
Yes - recall up to 
3 years allowed  
No - not 
applicable due 
to study design
Yes No Yes Very low
Bamji 
2008
Low - 
Retrospective 
and prospective 
cohort
Yes - 30% of 
selected women 
were not 
reachable and 
thus excluded 
from study
Yes - 
assessment 
conducted 1-2 
months after 
delivery.
Yes - 30% of 
selected women 
were Not 
reachable and 
thus excluded 
from study
No - Proportions 
presented. No 
control for 
confounding.
Yes - excluded 7 
children who 
died on day 1.
Yes Very low
Caglar 
2006
Low - Case 
control
No No
No - not 
applicable due 
to study design
No Yes Yes Very low
Clemens 
1999
Low - 
Prospective 
cohort
No
No - median age 
at enrollment 
was 11 days 
(IQR 7-16).
No -loss to 
follow up = 10%
No - Adjusted 
models do not 
include preterm 
or low 
birthweight 
status.
Yes - Median 
age at 
enrollment was 
11 days.
No Low
Dewey 
2003
Low - 
Prospective 
cohort
No No No
Not for our 
exposure and 
outcome of 
interest
Not for our 
exposure and 
outcome of 
interest
Yes Very low
Edmond 
2006
Low - 
Prospective 
cohort (within 
RCT)
No
No - median 
assessment at 
14 days 
postpartum
No Yes Yes Yes Moderate
Engebretsen 
2008
Low - Cross-
sectional
Yes - cross 
sectional
No
No - not 
applicable due 
to study design
No No Yes Very low
Enzunga 
1990
Low - 
Prospective 
cohort
unclear unclear unclear No No Yes Very low
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Appendix 2 – Table 2B (continued). Quality Assessment of Included Studies 
Study
Score for 
study design
 Risk of 
selection 
bias?
 Risk of 
information 
bias?
 Risk of 
attrition bias?
 Adequate 
adjustment 
for 
confounding?
 Accounted 
for reverse 
causality?
Should the 
score for 
study design 
be adjusted 
for study 
quality?
Score after 
adjustment
Garcia 
2011
Low - 
Prospective 
cohort
No No No Yes Yes Yes Moderate
Hajeebhoy 
2014
Low - Cross-
sectional
Yes - cross 
sectional
Yes - median 
age as 
assessment was 
3.3 months
No - not 
applicable due 
to study design
No No Yes Very low
Meshram 
2012
Low - Cross-
sectional
Yes - cross 
sectional
No
No - not 
applicable due 
to study design
No Yes Yes Very low
Mullany 
2008
Low - 
Prospective 
cohort (within 
RCT)
No No No Yes Yes Yes Moderate
Mullany 
2010
Low - 
Prospective 
cohort (within 
RCT)
No No No Yes Yes Yes Moderate
Mullany 
2009
Low - 
Prospective 
cohort (within 
RCT)
No No
No (89% of 
infants receive 
all 6 
assessments)
Yes Yes Yes Moderate
Neovita 
2016
[Includes:
Edmond 2015
Masanja 2015
Mazunder 2015]
Low - 
Prospective 
cohort (within 
RCT)
No No Very low LTFU Yes
Early deaths 
excluded
Yes Moderate
Niswade 
2011
Low - 
Prospective 
cohort
No
No - visited on 
day 0 and day 1
No Yes No Yes Very low
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Appendix 2 – Table 2B (continued). Quality Assessment of Included Studies  
Study
Score for 
study design
 Risk of 
selection 
bias?
 Risk of 
information 
bias?
 Risk of 
attrition bias?
 Adequate 
adjustment 
for 
confounding?
 Accounted 
for reverse 
causality?
Should the 
score for 
study design 
be adjusted 
for study 
quality?
Score after 
adjustment
Shah 
2014
Low - 
Prospective 
cohort (within 
RCT)
No
No - visisted on 
day of birth
No (~10% 
exlcuded due to 
missing LMP)
Yes Yes Yes Moderate
Sutan 
2014
Low - Case 
control
No
Yes - 
retrospective 
assessment of 
breastfeeding 
after child death
No - not 
applicable due 
to study design
Yes No Yes Very low
Van den Bosch
1990
High - 
Randomized 
Control Trial
No No
No (~11% 
missing 24 hour 
measurement)
N/A (due to 
study design)
Yes - preterm, 
low birthweight, 
and low Apgar 
score infants 
excluded
Yes High
Wren 
2015
Low - Cross-
sectional
Yes - cross 
sectional
No
No - not 
applicable due 
to study design
No Yes Yes Very low
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ABSTRACT 
Background: Although breastfeeding has known benefits for HIV-exposed infants, there is 
conflicting evidence regarding the benefits or harms for HIV-infected, breastfeeding mothers. 
Objective: To assess the relationship between feeding practices and the incidence of maternal 
mortality, morbidity, and indicators of poor nutritional status from six weeks to two years 
postpartum among women in Tanzania living with HIV.  
Methods: Prospective cohort design with Cox proportional hazards models. 
Results: At six weeks, three months, and six months postpartum, 85%, 59%, and 13% of women 
respectively reported exclusively breastfeeding; 91%, 74%, and 25% of women respectively 
reported any breastfeeding. We found an increased risk of wasting (BMI < 18.5) for women 
exclusively breastfeeding or continuing any breastfeeding at six weeks, three months, and six 
months postpartum. Women breastfeeding at six months had a 44% increased risk of wasting 
(95% CI: 1.00-2.06, p-value 0.05) through two years postpartum. This association was not 
modified by triple antiretroviral therapy (ART) use. Breastfeeding at six weeks was associated 
with reduced risk of severe anemia among ART users (adjusted HR 0.28, 95% CI: 0.09-0.86), 
while it was associated with a non-significant increased risk of severe anemia among non-ART 
users (adjusted HR 1.95, 95% CI: 0.47-8.06) (p value for interaction 0.04).  
Conclusion: Although breastfeeding has proven benefits for infant health, there may be a mixed 
impact on health outcomes for HIV-infected women. Based on existing evidence, we conclude 
that there is no clear evidence of strong benefits or harm associated with breastfeeding for HIV-
infect women. Additional research is needed to know if HIV-infected women may benefit from 
nutritional support, in addition to ART, during and after lactation. 
Key Words: HIV, Breastfeeding, Mortality, Morbidity, Anemia, Weight Loss
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Introduction 
UNAIDS estimates that 92% of pregnant women living with HIV reside in sub-Saharan Africa 
where maternal mortality and HIV prevalence are highest [1]. HIV is known to substantially 
increase the risk of poor nutritional outcomes and maternal morbidity, and it is estimated to 
increase maternal mortality by as much as five or ten-fold [2, 3].   
 
Despite recommendations that HIV-infected women receiving antiretroviral therapy exclusively 
breastfeed infants for six months, and continue breastfeeding through twelve months [4], there is 
conflicting evidence about the effect of breastfeeding on the risk of maternal mortality and 
morbidity in the postpartum period. However, some hypothesize that the metabolic demands of 
lactation, in conjunction with HIV, may result in poor health outcomes for women. A 
randomized trial of breastfeeding versus formula feeding in Kenya found that mortality among 
women randomized to breastfeeding was more than three times higher than among women 
randomized to formula feeding [5]. In contrast, a randomized trial in Botswana found no 
difference in maternal mortality between breastfeeding and formula feeding groups [6], and a 
randomized trial conducted in Zambia of prolonged feeding versus abrupt cessation of 
breastfeeding at four months postpartum also showed no difference in  maternal mortality [7]. 
Additional observational studies [8-10] and a meta-analysis [11] found no significant difference 
in the risk of mortality for women breastfeeding versus not breastfeeding (comparing ever versus 
never, or recent feeding versus not).   
   
Similarly, the evidence regarding the relationship between breastfeeding and maternal morbidity 
is conflicting. The Kenyan trial which noted increased risk of mortality for breastfeeding HIV-
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infected women also found increased risk of lactation-associated weight loss within two years of 
delivery [5]. Another study found significantly faster weight loss and CD4 cell count decline in 
breastfeeding women [12], while other studies have found no association with nutritional 
outcomes [9, 13]. Data linking breastfeeding to maternal anemia is limited, although one study 
suggests that prolonged breastfeeding for six months or more is an independent predictor of 
postpartum severe anemia in women with HIV [14]. Few studies have examined the relationship 
between prolonged breastfeeding (six months or more), which is currently recommended for 
HIV-infected mothers by infant feeding guidelines, and maternal health. 
 
In this study, we examined the relationship between feeding practices and health in a prospective 
cohort of women living with HIV. Specifically, we assessed the associations between exclusive 
breastfeeding and any breastfeeding at six weeks, three months, and six months postpartum and 
mortality, morbidity, and indicators of poor nutritional status in women through two years 
postpartum.  
 
 
Methods 
Study Design and Population 
This prospective cohort consists of women whose children were enrolled in a micronutrient 
supplementation trial in Tanzania evaluating the effect on infant morbidity and mortality 
(NCT00197730). The design, implementation, and results of this trial, conducted between 
August 2004 and November 2007, are described elsewhere [15]. Briefly, women with HIV who 
presented to antenatal care prior to 32 weeks gestation were recruited to enroll in the trial. 
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Singleton infants were randomized between five and seven weeks after birth if no congenital 
abnormality prevented feeding and the mother intended to stay in the study area. Mothers and 
children were asked to attend monthly clinic visits to receive PMTCT services and participate in 
the study for two years following enrollment. Initially, antiretroviral therapy was limited to 
single dose nevirapine prophylaxis for PMTCT. However, in July 2005, women with CD4 cell 
count <200 cell/uL or WHO stage III and CD4 cell count <350 cell/uL were eligible to begin 
triple antiretroviral therapy (ART). In accordance with the Tanzanian standard of care at the time 
of the trial, mothers were counseled on both the risks and benefits of exclusive breastfeeding, 
and those who chose to exclusively breastfeed were instructed not to give any additional foods or 
fluids aside from medicines or oral rehydration solutions [15]. 
 
Exposure Assessment and Definitions  
Breastfeeding was assessed longitudinally by the mother’s report during monthly clinic visits. 
Specifically, the mother was asked if the child consumed any foods from a specified list of 17 
items (e.g. breast milk, water, cow’s milk, formula, juice, etc.) during the previous week. The 
duration of exclusive breastfeeding and breastfeeding were defined as the midpoint between the 
last report of breastfeeding or exclusive breastfeeding and the first report of not breastfeeding or 
not exclusive breastfeeding. Exclusive breastfeeding and any breastfeeding were analyzed as 
binary exposures at six weeks, three months (90 days), and six months (180 days). Exclusive 
breastfeeding women were compared to not exclusively breastfeeding women (i.e. predominant, 
partial, and non-breastfeeding women). Breastfeeding women were compared to non-
breastfeeding women. 
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Outcome Assessment and Definitions 
Outcomes of interest included time to death, first hospitalization, first outpatient visit, wasting, 
anemia, and severe anemia. We included events only if they occurred after the time of exposure 
assessment. Data regarding morbidity were recorded by study nurses and physicians during study 
visits. Women were asked if they had been hospitalized or sought healthcare since the last study 
visit, and the date of hospital admission or outpatient visit was either abstracted from the 
woman’s medical card or reported by the woman.  
Weight and height were measured by study nurses at each study visit. Body mass index (BMI) 
was calculated as the weight in kilograms divided by height in meters squared. Excessive weight 
loss was examined by assessing cases of incident wasting, defined as a BMI of <18.5 [16]. 
Women with at least two weight measurements occurring 28 days after birth and who did not 
have a BMI <18.5 at their first postpartum weight measurement were included in the wasting 
analysis. Women were scheduled to give blood for a complete blood count at baseline, one year, 
and two years after delivery. Hemoglobin concentration was measured by the AcT5 Diff AL 
hematology analyzer (Beckman Coulter). Women with at least two measurements and who were 
not anemic (defined as Hb <11 g/dL) or severely anemic (defined as Hb <8 g/dL) at baseline 
were included in the anemia and severe anemia analyses. Women without events were censored 
at the time of their last study visit (maximum of 756 days) or at the time of death of their child. 
 
Statistical Analysis 
The cohort was characterized using baseline data regarding household, maternal and infant 
characteristics by means or proportions for continuous and categorical data respectively. 
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To examine the relationship between breastfeeding (exclusive breastfeeding or any 
breastfeeding) and each of the outcomes, Cox proportional hazard models were used [17]. 
Potential confounders included in the multivariate models were: use of antiretrovirals during 
pregnancy (yes, no), time-varying CD4 T-cell count (<200 cells/mm3, 200–349 cells/mm3, >350 
cells/mm3), birth weight of recent delivery (<2500 grams,  >2500 grams), gestational age at 
delivery (<37 weeks, >37weeks), whether the woman was primigravida (yes , no), woman’s 
education (<primary school completed or  >primary school completed), and marital status 
(married or living together vs not). We non-parametrically examined potential non-linear 
relationships between maternal age and each outcome with restricted cubic splines [18]. We 
tested non-linearity using the likelihood ratio test comparing the model with the linear term to 
the model with the linear plus cubic spline terms. In the case that the relationship was neither 
non-linear nor linear, we included age as a dichotomous variable (<27 years, >27 years). We 
assessed effect modification by antiretroviral use (initiated prior to or during pregnancy and 
continued thereafter versus not). To determine whether effect modification was statistically 
significant in the Cox proportional hazard models, we used a likelihood ratio test with one degree 
of freedom to compare the full model (with interaction term) to the reduced model (without 
interaction term). The missing indicator method was used for any missing confounders [19]. All 
hypothesis tests were two-sided, and a p value of <0.05 was considered significant. Analyses 
were performed using SAS software version 9.2 (Cary, NC). 
 
Ethics  
Written informed consent was obtained from all women participating in the parent trial. The trial 
protocol was approved by the institutional review boards of the Harvard School of Public Health, 
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Muhimbili University of Health and Allied Sciences, Tanzania Food and Drug Authority, and the 
Tanzania National Institute of Medical Research. 
Results 
A total of 2387 women were enrolled in the parent trial, and 2385 women were included in this 
study.  Two women were excluded because one woman never had breastfeeding status 
ascertained and one woman died prior to the first study visit at six weeks postpartum. The 
proportion of women exclusively breastfeeding at six weeks postpartum was 85% (n=2035), 
59% (n=1399) at three months, and 13% (n=320) at six months. The proportions of women who 
reported any breastfeeding at six weeks, three months, and six months were 91% (n=2164), 74% 
(n=1764), and 25% (n=602) respectively. The mean duration of exclusive breastfeeding in the 
study population was 3.5 months (SD 2.1) and the mean duration of any breastfeeding was 4.4 
months (SD 2.5). 
 
The mean age of women at baseline (six weeks postpartum) was 28 years (SD 5). The majority 
completed at least primary school. More than 60% of all mothers were women without income, 
and about half were married or living with a partner. Approximately 23% of women were 
pregnant with their first child. A total of 165 women received triple antiretroviral therapy in 
pregnancy, and the median CD4 count at baseline was 468 cells/mm3. Baseline characteristics 
were similar between those exclusively breastfeeding at six weeks and those who were not 
(Table 3.1).   
 
A total of 33 women (1.4%) died, 55 women (2.3%) were hospitalized, and 297 women (12.5%) 
attended a health facility outside of the normal study schedule during the two year follow-up 
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 Exclusively 
Breastfeeding
at 6 Weeks 
(n=2035)
Not Exclusively 
Breastfeeding 
at 6 Weeks 
(n=350)
Mean age (y) [mean (SD)] 28 (5) 29 (5)
Gestational age at enrollment (wk) [mean (SD)] 39 (3) 39 (3)
Education [n (%)]
Did not complete primary school 269 (13.2) 33 (9.4)
Completed primary school or more 1748 (85.9) 313 (89.4)
Employment [n (%)]
Business woman 104 (5.1) 26 (7.4)
Housewife with income 175 (8.6) 25 (7.1)
Housewife without income 1320 (64.9) 207 (59.1)
Other 372 (18.3) 68 (19.4)
Married/living with partner [n (%)] 1054 (51.8) 175 (50.0)
Prima gravida [n (%)] 454 (22.3) 86 (24.6)
Midupper arm circumference (cm) [mean (SD)] 26 (3) 26 (3)
Hemoglobin 
>11 g/dL [n (%)] 1301 (63.9) 176 (50.3)
Concentration [mean (SD)] 12 (1) 11 (1)
BMI group [n (%)]
<18.5 kg/m
2 
94 (4.6) 17 (4.9)
18.5 to <25 kg/m
2 
1219 (59.9) 201 (57.4)
25.0 to <30 kg/m
2 
555 (27.3) 96 (27.4)
>30 kg/m
2 
163 (8.0) 163 (8.0)
Received ART during pregnancy [n (%)] 126 (6.2) 39 (11.1)
WHO disease stage I/II [n (%)] 1075 (52.8) 179 (51.1)
CD4 count [median (IQR)] 471 [327-679] 434 [284-640]
CD4 count [n (%)]
<200 cells/mm 43 (12.3) 155 (7.6)
200–349 cells/mm 63 (18.0) 358 (17.6)
>350 cells/mm 179 (51.1) 1303 (64.0)
Male child [n (%)] 1100 (54.1) 187 (53.4)
Child born < 37 weeks [n (%)] 310 (15.2) 47 (13.3)
Birthweight <2.5 kg [n (%)] 130 (6.4) 31 (8.9)
a
 Percents may not add to 100% due to missing data
Table 3.1. Baseline demographic and health characteristics stratified by exclusive 
breastfeeding status at six weeks postpartum (n=2385)
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period. We found no significant association between exclusive breastfeeding (compared to non-
exclusive breastfeeding and no breastfeeding) or any breastfeeding (compared to no 
breastfeeding) and the risk of death or outpatient visits at six weeks, three months, or six months. 
However, we found that exclusive breastfeeding at six weeks was significantly associated with a 
47% reduced risk of hospitalization (adjusted HR 0.53, 95% CI: 0.29-0.99). Similarly, exclusive 
breastfeeding at three months was independently associated with a reduced risk of hospitalization 
(adjusted HR 0.54, 95% CI: 0.29-0.99) (Table 3.2). 
 
We examined ART use during pregnancy as a potential effect modifier for morbidity and 
mortality outcomes. We found that the reduced risk of hospitalizations associated with exclusive 
breastfeeding at six weeks was limited to women who did not use ART (adjusted HR 0.39, 95% 
CI: 0.18-0.82) (p value for interaction 0.03) (Table 3.3). Similarly, the risk of hospitalization 
associated with exclusive breastfeeding at three months was significantly reduced among women 
not using ART (adjusted HR 0.45, 95% CI: 0.21-0.94) (p value for interaction 0.04) (Table 3.4). 
 
Most women (n=2318) had at least two postpartum weight measurements taken more than four 
weeks after delivery. Among these women, 101 (4.4%) had a BMI of <18.5 at baseline and were 
excluded from the analysis. A total of 2217 women were included in the wasting analysis.  
Among these women, 277 (12.5%) had a change in BMI to <18.5 over the course of follow-up.  
Women who were still breastfeeding at six months had a 44% increased risk of wasting 
compared to women who had stopped breastfeeding (95% CI: 1.00-2.06).
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Outcome HR  (95% CI) p value HR
a
  (95% CI) p value HR  (95% CI) p value HR
a
  (95% CI) p value
Breastfeeding at Six Weeks
Mortality 33 2385 0.50 (0.22,1.10) 0.08 0.60 (0.26,1.37) 0.23 0.50 (0.19,1.28) 0.15 0.62(0.23,1.66) 0.34
Hospitalization 55 2385 0.45 (0.25,0.83) 0.01 0.53 (0.29,0.99) 0.05 0.60 (0.27,1.33) 0.21 0.80 (0.35,1.82) 0.59
Outpatient Visit 297 2385 0.81 (0.60,1.11) 0.19 0.85 (0.62,1.16) 0.30 0.79 (0.54,1.15) 0.22 0.83 (0.57,1.23) 0.35
Wasting
b
277 2217 1.21 (0.84,1.75) 0.31 1.28 (0.88,1.86) 0.19 1.16 (0.74,1.83) 0.51 1.29 (0.81,2.05) 0.28
Anemia
c
437 1211 1.07 (0.80,1.43) 0.65 1.05 (0.78,1.41) 0.74 0.98 (0.68,1.40) 0.90 0.98 (0.68,1.41) 0.90
Severe Anemia
d
71 1709 1.08 (0.54,2.17) 0.84 1.14 (0.56,2.32) 0.71 0.80 (0.36,1.74) 0.57 0.89 (0.40,1.98) 0.77
Breastfeeding at Three Months
Mortality 29 2196 0.51 (0.24,1.05) 0.07 0.52(0.24,1.12) 0.09 0.49 (0.23,1.04) 0.06 0.51(0.23,1.1) 0.09
Hospitalization 42 2184 0.51 (0.28,0.94) 0.03 0.54 (0.29,0.99) 0.05 0.54 (0.29,1.01) 0.05 0.59 (0.31,1.13) 0.11
Outpatient Visit 227 2128 0.84 (0.64,1.09) 0.19 0.86 (0.66,1.12) 0.27 0.75 (0.56,1.00) 0.05 0.76 (0.56,1.02) 0.06
Wasting
b
190 2017 1.15 (0.85,1.55) 0.36 1.20 (0.89,1.62) 0.24 1.18 (0.83,1.67) 0.36 1.24 (0.87,1.77) 0.24
Anemia
c
437 1209 1.15 (0.95,1.40) 0.16 1.15 (0.94,1.40) 0.17 1.08 (0.86,1.36) 0.49 1.08 (0.86,1.37) 0.49
Severe Anemia
d
71 1704 1.20 (0.73,1.96) 0.47 1.29 (0.78,2.11) 0.32 1.12 (0.63,1.98) 0.70 1.20 (0.67,2.14) 0.53
Breastfeeding at Six Months
Mortality 25 2031 1.08 (0.37,3.13) 0.89 0.85(0.28,2.6) 0.78 0.67 (0.25,1.79) 0.42 0.5(0.18,1.38) 0.18
Hospitalization 30 2008 0.63 (0.19,2.06) 0.44 0.69 (0.21,2.29) 0.55 0.29 (0.09,0.96) 0.04 0.32 (0.10,1.06) 0.06
Outpatient Visit 176 1918 0.94 (0.61,1.43) 0.76 0.93 (0.60,1.42) 0.72 0.79 (0.56,1.13) 0.20 0.79 (0.55,1.12) 0.19
Wasting
b
137 1818 1.10 (0.70,1.73) 0.69 1.18 (0.75,1.87) 0.48 1.37 (0.96,1.95) 0.08 1.44 (1.00,2.06) 0.05
Anemia
c
430 1200 1.06 (0.82,1.37) 0.67 1.08 (0.83,1.41) 0.56 1.02 (0.82,1.26) 0.86 1.04 (0.84,1.29) 0.73
Severe Anemia
d
68 1699 1.33 (0.73,2.43) 0.36 1.37 (0.75,2.51) 0.31 1.29 (0.77,2.14) 0.33 1.27 (0.76,2.13) 0.36
d
 Severe anemia defined as <8 g/dl
Univariate Multivariate Univariate MultivariateN              
total 
Table 3.2. Exclusive breastfeeding (compared to predominant, partial, and no breastfeeding) or any breasteeding (compared to no 
breastfeeding) - at six weeks, three months, six months - in relation to maternal mortality, first hospitalization, first outpatient visit, wasting  
(BMI < 18.5), anemia diagnosis (Hgb < 11g/dL), and severe anemia diagnosis (Hgb < 8g/dL).
a
 Time-varying CD4, ARV  during pregnancy  (yes/no), birthweight  (<2500g yes/no), gestational age at delivery  (<37 weeks yes/no), prima gravida  
(yes/no), woman's age  (>28 yes/no), woman's education  (< primary school completed yes/no)
b 
Wasting defined as BMI < 18.5
c
 Anemia defined as <11 g/dl
Exclusive Breastfeeding
(Compared to Predominant, Partial, or No Breastfeeding)
Any Breastfeeding
(Compared to No Breastfeeding)
n              
event
s
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Outcome
n              
events
N              
total 
HR
a
  (95% CI) p value
p value
interaction
HR
a
  (95% CI) p value
p value
interaction
Mortality
ARV Use 7 428 0.59 (0.09, 3.86) 0.58 0.36 (0.05, 2.46) 0.30
No ARV Use 17 1692 0.55 (0.15, 1.96) 0.36 0.94 (0.12, 7.29) 0.96
Hospitalization
ARV Use 17 428 2.43 (0.51, 11.60) 0.27 2.98 (0.38, 23.30) 0.30
No ARV Use 34 1692 0.39 (0.18, 0.82) 0.01 0.53 (0.20, 1.40) 0.20
Outpatient Visit
ARV Use 66 428 0.70 (0.39, 1.27) 0.24 0.53 (0.28, 1.00) 0.05
No ARV Use 218 1692 1.12 (0.74, 1.70) 0.59 1.27 (0.72, 2.24) 0.40
Wasting
b
ARV Use 68 402 1.14 (0.60, 2.15) 0.69 1.18 (0.57, 2.42) 0.66
No ARV Use 192 1600 1.30 (0.81, 2.09) 0.28 1.32 (0.69, 2.50) 0.40
Anemia
c
ARV Use 72 219 0.71 (0.39, 1.32) 0.29 0.60 (0.31, 1.17) 0.14
No ARV Use 359 976 1.19 (0.84, 1.67) 0.32 1.25 (0.79, 1.96) 0.34
Severe Anemia
d
ARV Use 16 350 0.42 (0.14, 1.25) 0.12 0.28 (0.09, 0.86) 0.03
No ARV Use 54 1332 1.83 (0.66, 5.08) 0.25 1.95 (0.47, 8.06) 0.36
Table 3.3.  Exclusive breastfeeding (compared to predominant, partial, and no breastfeeding) or any breasteeding (compared 
to no breastfeeding) -at six weeks - in relation to maternal mortality, wasting, anemia, severe anemia, first hospitalization, 
and first outpatient visit during the first 2 years after delivery - stratified by ARV use.
0.86
0.69
0.21
0.07 0.04
0.10
0.77
0.39
Exclusive Breastfeeding Any Breastfeeding
0.03
0.26 0.10
0.06
d
 Severe anemia defined as <8 g/dl
a Adjusted for time-varying CD4, birthweight  (<2500g yes/no), gestational age at delivery  (<37 weeks yes/no), prima 
gravida  (yes/no), woman's age  (>28 yes/no), woman's education  (< primary school completed yes/no)
b 
Wasting defined as BMI <18.5
c
 Anemia defined as <11 g/dl
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Outcome
n              
events
N              
total 
HR
a
  (95% CI) p value
p value
interaction
HR
a
  (95% CI) p value
p value
interaction
Mortality
ARV Use 6 409
e 0.06 (0.01, 0.76) 0.03
No ARV Use 15 1635 1.10 (0.37, 3.24) 0.87 1.55 (0.34, 6.98) 0.57
Hospitalization
ARV Use 12 405 1.25 (0.38, 4.07) 0.72 1.42 (0.37, 5.45) 0.61
No ARV Use 28 1629 0.45 (0.21, 0.94) 0.04 0.52 (0.24, 1.14) 0.10
Outpatient Visit
ARV Use 49 393 0.74 (0.42, 1.32) 0.31 0.68 (0.38, 1.24) 0.21
No ARV Use 170 1588 0.97 (0.71, 1.33) 0.86 0.83 (0.58, 1.17) 0.29
Wasting
b
ARV Use 50 374 1.43 (0.81, 2.53) 0.22 1.50 (0.80, 2.84) 0.21
No ARV Use 131 1507 1.05 (0.73, 1.50) 0.81 1.13 (0.73, 1.75) 0.59
Anemia
c
ARV Use 72 218 1.32 (0.82, 2.15) 0.26 1.07 (0.64, 1.81) 0.79
No ARV Use 359 975 1.12 (0.90, 1.40) 0.30 1.10 (0.84, 1.43) 0.49
Severe Anemia
d
ARV Use 16 346 0.50 (0.18, 1.41) 0.19 0.78 (0.27, 2.24) 0.64
No ARV Use 54 1331 1.66 (0.90, 3.06) 0.10 1.34 (0.65, 2.75) 0.42
0.150.16
0.81
0.37
0.04
0.37
b 
Wasting defined as BMI <18.5
c
 Anemia defined as <11 g/dl
0.76
0.40
0.45
0.25
a Adjusted for time-varying CD4, birthweight  (<2500g yes/no), gestational age at delivery  (<37 weeks yes/no), prima 
gravida  (yes/no), woman's age  (>28 yes/no), woman's education  (< primary school completed yes/no)
0.07
d
 Severe anemia defined as <8 g/dl
e
 Hazard ratio and 95% CI not estimable. No events in the (exclusive) breastfeeding group.
Any Breastfeeding
Table 3.4.  Exclusive breastfeeding (compared to predominant, partial, and no breastfeeding) or any breasteeding (compared 
to no breastfeeding) -at three months - in relation to maternal mortality, wasting, anemia, severe anemia, first hospitalization, 
and first outpatient visit during the first 2 years after delivery - stratified by ARV use.
Exclusive Breastfeeding
0.86
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Approximately 73% of women (n=1734) had at least two postpartum complete blood count 
measurements and were thus eligible for inclusion in the anemia analysis. Among these women, 
523 had a hemoglobin count of <11 g/dL at baseline and were excluded from the analysis. 
Among the 1211 women included in the analysis of anemia, there were 437 (36%) incident cases 
of anemia over the course of follow-up. Univariate and multivariate analysis showed no 
relationship between exclusive breastfeeding or any breastfeeding at any time with anemia 
(Table 3.2). 
 
Of the 1734 women who had at least two postpartum CBC measurements, 25 had a hemoglobin 
count of <8 g/dL at baseline and were excluded from the analysis of severe anemia. A total of 
1709 women were included in the analysis of severe anemia, and 71 women (4.2%) experienced 
an incident case of severe anemia. Overall, there was no relationship between exclusive 
breastfeeding or any breastfeeding and severe anemia, but there appeared to be effect 
modification by ART use (Table 3.2). Exclusive breastfeeding and breastfeeding were associated 
with a reduced risk of severe anemia among women using ART, while they were associated with 
an increased risk of severe anemia among women not using ART (Tables 3.3,3.4,3.5). For 
example, breastfeeding at six weeks (compared to no breastfeeding at six weeks) was associated 
with a 72% reduced risk of severe anemia among ART users (95% CI: 0.09-0.86), while 
breastfeeding at six weeks (compared to no breastfeeding at six weeks) was associated with an 
increased risk of severe anemia among non-ART users (adjusted HR 1.95, 95% CI: 0.47-8.06) (p 
value for interaction 0.04) (Table 3.3). 
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Outcome
n              
events
N              
total 
HR
a
  (95% CI) p value
p value
interaction
HR
a
  (95% CI) p value
p value
interaction
Mortality
ARV Use 4 388
e e 
No ARV Use 15 1568 1.17 (0.32, 4.24) 0.81 0.78 (0.24, 2.51) 0.68
Hospitalization
ARV Use 9 381
e e 
No ARV Use 20 1554 1.03 (0.30, 3.52) 0.97 0.51 (0.15, 1.75) 0.29
Outpatient Visit
ARV Use 40 363 0.53 (0.16, 1.77) 0.30 0.55 (0.24, 1.26) 0.15
No ARV Use 133 1488 1.08 (0.68, 1.71) 0.75 0.86 (0.58, 1.29) 0.47
Wasting
b . . . .
ARV Use 36 341 1.22 (0.47, 3.21) 0.68 1.49 (0.73, 3.07) 0.28
No ARV Use 98 1414 1.13 (0.66, 1.94) 0.65 1.37 (0.89, 2.10) 0.15
Anemia
c
ARV Use 71 216 1.58 (0.80, 3.12) 0.19 0.96 (0.55, 1.68) 0.88
No ARV Use 353 968 1.01 (0.76, 1.35) 0.95 1.06 (0.84, 1.34) 0.62
Severe Anemia
d
ARV Use 15 344 0.80 (0.17, 3.74) 0.77 0.66 (0.18, 2.41) 0.52
No ARV Use 52 1328 1.52 (0.78, 2.96) 0.22 1.56 (0.88, 2.76) 0.13
0.07
a Adjusted for time-varying CD4, birthweight  (<2500g yes/no), gestational age at delivery  (<37 weeks yes/no), prima 
gravida  (yes/no), woman's age  (>28 yes/no), woman's education  (< primary school completed yes/no)
b 
Wasting defined as BMI <18.5
c
 Anemia defined as <11 g/dl
0.07
0.12
0.96
0.71
0.18
0.04
0.18
0.15
0.86
0.25
0.43
e
 Hazard ratio and 95% CI not estimable. No events in the (exclusive) breastfeeding group.
d
 Severe anemia defined as <8 g/dl
Exclusive Breastfeeding Any Breastfeeding
Table 3.5.  Exclusive breastfeeding (compared to predominant, partial, and no breastfeeding) or any breasteeding (compared 
to no breastfeeding) -at six months - in relation to maternal mortality, wasting, anemia, severe anemia, first hospitalization, 
and first outpatient visit during the first 2 years after delivery - stratified by ARV use.
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Discussion 
Our study identified mixed health effects associated with breastfeeding among HIV-infected 
women in Tanzania. Breastfeeding was weakly associated with increased risk of wasting among 
all women and increased risk of severe anemia among women without ART access. We also 
found lower risk for hospitalization among women who exclusively breastfed for three months or 
more. We found no increased risk of mortality in relation to breastfeeding among this study 
population; this is consistent with other observational data [9-11].  
 
Undernutrition and anemia are major public health problems in low-income countries and 
contribute substantially to maternal morbidity and mortality; they are associated with disease 
progression and decreased survival in people living with HIV [20-27]. We found a significant, 
elevated risk of wasting (BMI <18.5) associated with breastfeeding for six months or more, and 
similar, although non-significant, risk estimates associated with exclusive breastfeeding and 
breastfeeding at other time points. This relationship was not modified by ART use. We saw the 
highest risk of wasting among women breastfeeding six months or more, which is consistent 
with research showing that lactation-associated fat mobilization and weight loss increase 
substantially after the first three months postpartum [28]. Similarly, HIV-infected, breastfeeding 
women in Kenya experienced faster weight loss compared to non-breastfeeding peers [12]. 
Although a recent meta-analysis including studies from high- and low-income countries found no 
clear relationship between breastfeeding and maternal weight change [29], there is some 
evidence to suggest that women with HIV may be more susceptible to lactation-associated 
weight loss. For example, among a cohort of breastfeeding women in South Africa, women with 
HIV had a mean weight loss of 1.4 kg, compared to 0.4 kg weight gain in HIV-uninfected 
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women between eight and 24 weeks postpartum [30]. In contrast, studies from Tanzania and 
Zambia found no relationship between breastfeeding and wasting among cohorts of HIV-infected 
women [9, 31]. Additional research is needed to understand the relationship between 
breastfeeding—especially prolonged breastfeeding (six months or more)—and the risk of excess 
weight loss among HIV-infected women. Pre-pregnancy health and nutritional status, as well as 
postpartum dietary intake, should be carefully incorporated into future analyses. 
 
Concerns about poor maternal health among breastfeeding women with HIV are supported by 
the concept of reproductive stress or “maternal depletion syndrome,” which suggest that 
pregnancy and lactation may cause poor health outcomes for women [32]. Though limited 
research suggests that metabolic adaptation allows lactating women to maintain energy balance, 
even in the presence of illness or undernutrition [33, 34], it is not clear if this is true for HIV-
infected women. In fact, resting energy expenditure has been shown to be higher in HIV-infected 
women when compared to HIV-uninfected women [35]. Further, there is no specific data 
regarding resting energy expenditure or total daily energy expenditure among pregnant and 
lactating women with HIV who are subject to additional metabolic demands [36].   
 
Pregnant women are at high risk for anemia [37], and women with HIV are particularly 
susceptible due to HIV infection itself and AIDS-related infections [22, 23]. However, the 
relationship between breastfeeding and anemia risk in women with HIV is not well-studied. We 
found breastfeeding was associated with an increased risk of severe anemia among women who 
did not use ART and a reduced risk of severe anemia among women who received ART. In 
general, ART reduces the risk of anemia [21, 38, 39], although regimens containing Zidovudine 
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(AZT) and Efavirenz (EFV) may increase the risk of anemia [40]. Our results are consistent with 
a multi-site trial conducted in Burkina Faso, Kenya, and South Africa, the Kesho Bora Trial, 
which found that prolonged breastfeeding (six months or longer) was associated with a 62% 
increase in the risk of severe anemia through 18 months postpartum compared with women who 
breastfed for less than six months; although some of these women were randomized to ART 
during pregnancy, they ceased use of ART at the time of breastfeeding cessation (up to six 
months postpartum) [14]. In addition to ART use, the relationship between breastfeeding and 
anemia is likely modified by baseline hemoglobin status and other components of antenatal care 
such as provision of iron-fortified replacement feeding, maternal use of anti-helminthics, 
intermittent preventive treatment of malaria, and micronutrient supplementation. Additional 
research regarding the interaction between breastfeeding, ART use, and anemia in postpartum 
women is needed. 
 
Breastfeeding was associated with a reduced risk of hospitalization in our study. However, our 
results must be interpreted cautiously since hospitalization is a measure of both morbidity and 
care-seeking behavior. There is evidence of longer-term health benefits for women who have 
breastfed, including reduced risk of type 2 diabetes [41], hypertension [42], hyperlipidemia [42], 
heart disease [42], breast cancer [29, 43], and ovarian cancer [29, 44]. But there is no clear 
biological mechanism to explain reduced risk of hospitalization among breastfeeding women in 
our study. We hypothesize that maternal reports of hospitalization may be linked to seeking care 
for the infant. Breastfeeding has significant infant health benefits [45-48], so the observed 
reduced risk of hospitalization may be the result of improved infant health. Further, measurement 
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of hospitalization, which is self-reported, is more susceptible to measurement error; it is not an 
objective health measure, such as body weight or hemoglobin status. 
 
Due to the observational study design, we cannot rule out residual confounding or the possibility 
that sicker women chose to stop breastfeeding (i.e. reverse causality). In addition, we did not 
assess breastfeeding and maternal health outcomes during the first six weeks postpartum. 
Additionally, we conducted multiple statistical tests which increases the probability that some of 
our findings may have occurred by chance. There are limitations in using observational data, but 
additional randomized trials to assess maternal health outcomes are unlikely due to current 
guidelines that promote breastfeeding given its clear benefits for HIV-exposed infants [4]. 
However, our study’s longitudinal design—with repeated assessment of all outcomes, and follow 
up until two years postpartum—is one of its strengths. Furthermore, breastfeeding was carefully 
assessed at monthly study visits, which limits recall bias. Finally, the sample size and number of 
events is large compared to previous research. 
 
Although breastfeeding has proven benefits for infant health, there may be a mixed impact on 
health outcomes for HIV-infected women. Based on existing evidence, we conclude that there is 
no clear evidence of strong benefits or harm associated with breastfeeding for HIV-infect 
women. Additional research is needed to know if HIV-infected women may require nutritional 
support, in addition to ART, during and after lactation. 
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